<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Psychopharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">464</journal-id><journal-id journal-id-type="pmc-domain">sageopen</journal-id><journal-id journal-id-type="publisher-id">JOP</journal-id><journal-title-group><journal-title>Journal of Psychopharmacology (Oxford, England)</journal-title></journal-title-group><issn pub-type="ppub">0269-8811</issn><issn pub-type="epub">1461-7285</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Sage Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10851641</article-id><article-id pub-id-type="pmcid-ver">PMC10851641.1</article-id><article-id pub-id-type="pmcaid">10851641</article-id><article-id pub-id-type="pmcaiid">10851641</article-id><article-id pub-id-type="pmid">37982394</article-id><article-id pub-id-type="doi">10.1177/02698811231211219</article-id><article-id pub-id-type="publisher-id">10.1177_02698811231211219</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>Drug&#8211;drug interactions involving classic psychedelics: A systematic review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5248-4121</contrib-id><name name-style="western"><surname>Halman</surname><given-names initials="A">Andreas</given-names></name><xref rid="aff1-02698811231211219" ref-type="aff">1</xref><xref rid="corresp1-02698811231211219" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kong</surname><given-names initials="G">Geraldine</given-names></name><xref rid="aff2-02698811231211219" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sarris</surname><given-names initials="J">Jerome</given-names></name><xref rid="aff3-02698811231211219" ref-type="aff">3</xref><xref rid="aff4-02698811231211219" ref-type="aff">4</xref><xref rid="aff5-02698811231211219" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perkins</surname><given-names initials="D">Daniel</given-names></name><xref rid="aff1-02698811231211219" ref-type="aff">1</xref><xref rid="aff5-02698811231211219" ref-type="aff">5</xref></contrib></contrib-group><aff id="aff1-02698811231211219"><label>1</label>Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia</aff><aff id="aff2-02698811231211219"><label>2</label>Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, VIC, Australia</aff><aff id="aff3-02698811231211219"><label>3</label>NICM Health Research Institute, Western Sydney University, Sydney, Australia</aff><aff id="aff4-02698811231211219"><label>4</label>Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia</aff><aff id="aff5-02698811231211219"><label>5</label>Psychae Institute, Melbourne, VIC, Australia</aff><author-notes><corresp id="corresp1-02698811231211219">Andreas Halman, Melbourne School of Population and Global Health, University of Melbourne, Grattan Street, Parkville, Melbourne, VIC 3010, Australia. Email: <email>andreas.halman@unimelb.edu.au</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2024</year></pub-date><volume>38</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">455396</issue-id><fpage>3</fpage><lpage>18</lpage><pub-history><event event-type="pmc-release"><date><day>08</day><month>02</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>09</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-17 15:25:15.170"><day>17</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_02698811231211219.pdf"/><abstract><p>Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes when using these substances in combination with other drugs is limited. This systematic review aims to provide a comprehensive overview of the current research on drug&#8211;drug interactions between classic psychedelics and other drugs in humans. We conducted a thorough literature search using multiple databases, including PubMed, PsycINFO, Web of Science and other sources to supplement our search for relevant studies. A total of 7102 records were screened, and studies involving human data describing potential interactions (as well as the lack thereof) between classic psychedelics and other drugs were included. In total, we identified 52 studies from 36 reports published before September 2, 2023, encompassing 32 studies on LSD, 10 on psilocybin, 4 on mescaline, 3 on DMT, 2 on 5-MeO-DMT and 1 on ayahuasca. These studies provide insights into the interactions between classic psychedelics and a range of drugs, including antidepressants, antipsychotics, anxiolytics, mood stabilisers, recreational drugs and others. The findings revealed various effects when psychedelics were combined with other drugs, including both attenuated and potentiated effects, as well as instances where no changes were observed. Except for a few case reports, no serious adverse drug events were described in the included studies. An in-depth discussion of the results is presented, along with an exploration of the potential molecular pathways that underlie the observed effects.</p></abstract><kwd-group><kwd>Hallucinogens</kwd><kwd>LSD</kwd><kwd>psilocybin</kwd><kwd>mescaline</kwd><kwd>5-MeO-DMT</kwd><kwd>DMT</kwd><kwd>ayahuasca</kwd><kwd>drug interactions</kwd><kwd>psychopharmacology</kwd><kwd>pharmacodynamics</kwd><kwd>pharmacokinetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-02698811231211219"><title>Introduction</title><p>Classic psychedelics include lysergic acid diethylamide (LSD), psilocybin (psilocin as an active agent), mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) (<xref rid="bibr21-02698811231211219" ref-type="bibr">Calvey and Howells, 2018</xref>). LSD has a high affinity for several serotonin (5-HT) receptors (such as 5-HT<sub>1A/B</sub> and 5-HT<sub>2A</sub>) and also has an affinity to dopaminergic D<sub>1&#8211;5</sub> receptors (<xref rid="bibr50-02698811231211219" ref-type="bibr">Halberstadt and Geyer, 2011</xref>). The affinity for 5-HT<sub>2A</sub> is important as the main mechanism behind the behavioural and psychological effects of LSD and other psychedelics is thought to be mediated through the activation of 5-HT<sub>2A</sub> receptors in cortical and subcortical structures (<xref rid="bibr104-02698811231211219" ref-type="bibr">Vollenweider and Smallridge, 2022</xref>). LSD is metabolised by cytochrome P450 (CYP) enzymes such as CYP1A2, CYP3A4, CYP2C9, CYP2C19 and CYP2D6, with particular emphasis on the primary contribution of the former two (<xref rid="bibr106-02698811231211219" ref-type="bibr">Wagmann et al., 2019</xref>).</p><p>While LSD is chemically synthesised, psilocybin is a naturally occurring psychedelic compound found in various genera of mushrooms, including <italic toggle="yes">Psilocybe, Panaeolus</italic>, <italic toggle="yes">Conocybe</italic>, <italic toggle="yes">Gymnopilus, Stropharia, Pluteus</italic> and <italic toggle="yes">Panaeolina</italic> (<xref rid="bibr29-02698811231211219" ref-type="bibr">Dinis-Oliveira et al., 2019</xref>). Once ingested, the body metabolises psilocybin to psilocin, which is the primary psychoactive compound (<xref rid="bibr28-02698811231211219" ref-type="bibr">Dinis-Oliveira, 2017</xref>). The metabolism of psilocybin involves several enzymes, including aldehyde dehydrogenase, monoamine oxidase (MAO) and UDP-glucuronosyltransferase (UGT) enzymes such as UGT1A9, UGT1A10, UGT1A6, UGT1A7 and UGT1A8 (<xref rid="bibr28-02698811231211219" ref-type="bibr">Dinis-Oliveira, 2017</xref>). Similar to LSD, psilocin acts as an agonist at 5-HT<sub>2A</sub> receptors in the brain (<xref rid="bibr88-02698811231211219" ref-type="bibr">Rickli et al., 2016</xref>), where it exerts its psychological effects (<xref rid="bibr105-02698811231211219" ref-type="bibr">F. X. Vollenweider et al., 1998</xref>).</p><p>Mescaline (3,4,5-trimethoxyphenethylamine) is a psychedelic compound found in the North American peyote cactus (<italic toggle="yes">Lophophora williamsii</italic>), the South American San Pedro cactus (<italic toggle="yes">Echinopsis pachanoi</italic>), as well as other cacti such as the Peruvian torch cactus (<italic toggle="yes">Echinopsis peruviana</italic>), Bolivian torch cactus (<italic toggle="yes">Echinopsis lageniformis</italic>) and the leaf cactus (<italic toggle="yes">Pereskia aculeata</italic>) (<xref rid="bibr29-02698811231211219" ref-type="bibr">Dinis-Oliveira et al., 2019</xref>). It has a high affinity for 5-HT<sub>1A</sub> and 5-HT<sub>2A/C</sub> receptors but is less potent than LSD, psilocin and DMT (<xref rid="bibr88-02698811231211219" ref-type="bibr">Rickli et al., 2016</xref>). Mescaline is metabolised in the liver and broken down into several inactive compounds, with oxidative deamination occurring via MAO or diamine oxidase (<xref rid="bibr29-02698811231211219" ref-type="bibr">Dinis-Oliveira et al., 2019</xref>).</p><p>DMT is a naturally occurring psychoactive compound found in several plants and is also endogenously produced in mammals, including humans (<xref rid="bibr59-02698811231211219" ref-type="bibr">Jim&#233;nez and Bouso, 2022</xref>). Recreationally, DMT is consumed either in a pure form (mostly smoked) or as a key ingredient in an orally active brew called ayahuasca (<xref rid="bibr18-02698811231211219" ref-type="bibr">Cakic et al., 2010</xref>). Ayahuasca is made by mixing a DMT-containing plant with a vine containing &#946;-carboline alkaloids (<xref rid="bibr15-02698811231211219" ref-type="bibr">Brito-da-Costa et al., 2020</xref>). Although the exact plant combinations can vary, a frequent mixture is made of <italic toggle="yes">Psychotria viridis</italic> (source of DMT) and <italic toggle="yes">Banisteriopsis caapi</italic> vine, whose stem and bark contain &#946;-carbolines harmine and harmaline (<xref rid="bibr15-02698811231211219" ref-type="bibr">Brito-da-Costa et al., 2020</xref>).</p><p>DMT is a partial agonist primarily of the 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors (<xref rid="bibr22-02698811231211219" ref-type="bibr">Carbonaro and Gatch, 2016</xref>). Oral consumption of DMT does not produce psychotropic effects due to rapid metabolism by MAO enzymes (<xref rid="bibr87-02698811231211219" ref-type="bibr">Riba et al., 2015</xref>). However, when consumed orally as part of the ayahuasca brew, DMT becomes bioavailable due to the MAO-A inhibiting effects of harmine and harmaline, which protect DMT from deamination in the gut (<xref rid="bibr15-02698811231211219" ref-type="bibr">Brito-da-Costa et al., 2020</xref>). DMT alone has a short half-life of 9&#8211;12&#8201;min and is rapidly metabolised by MAO-A, while CYP2D6 and, to a lesser extent, CYP2C19 are also involved in its metabolism (<xref rid="bibr44-02698811231211219" ref-type="bibr">Good et al., 2022</xref>).</p><p>Finally, 5-MeO-DMT is a psychedelic that has been detected in numerous plant and fungal sources, as well as in the gland secretions of the <italic toggle="yes">Incilius alvarius</italic> toad (<xref rid="bibr36-02698811231211219" ref-type="bibr">Ermakova et al., 2022</xref>). 5-MeO-DMT is a non-selective serotonin receptor agonist, exhibiting a strong affinity for 5-HT<sub>1A/1B/1D/6/7</sub> but a significantly lower affinity for 5-HT<sub>2A</sub> receptor subtype (<xref rid="bibr51-02698811231211219" ref-type="bibr">Halberstadt et al., 2012</xref>; <xref rid="bibr84-02698811231211219" ref-type="bibr">Ray, 2010</xref>). Both receptors, 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> activation, are involved in 5-MeO-DMT behavioural effects (<xref rid="bibr36-02698811231211219" ref-type="bibr">Ermakova et al., 2022</xref>). 5-MeO-DMT has been observed to robustly inhibit the reuptake of serotonin but also dopamine and norepinephrine while demonstrating minimal activity in terms of releasing these three compounds (<xref rid="bibr73-02698811231211219" ref-type="bibr">Nagai et al., 2007</xref>). The primary process by which 5-MeO-DMT is metabolised involves oxidative deamination catalysed by MAO-A, leading to the formation of 5-methoxyindoleacetic acid. In addition, a minor portion of 5-MeO-DMT undergoes O-demethylation via CYP2D6 to produce bufotenine (5-hydroxy-DMT) (<xref rid="bibr49-02698811231211219" ref-type="bibr">Halberstadt, 2016</xref>) which is a potent 5-HT<sub>2A</sub> agonist (<xref rid="bibr33-02698811231211219" ref-type="bibr">Egan et al., 2000</xref>).</p><p>Drug&#8211;drug interactions (DDIs) can be categorised as either pharmacokinetic or pharmacodynamic interactions. Pharmacokinetic interactions occur when one drug influences the absorption, distribution, metabolism or elimination of another drug. On the other hand, pharmacodynamic interactions involve the modification of the pharmacological effect of one drug by another. These interactions can exhibit synergistic, additive or antagonistic characteristics. Additivity refers to the overall effect of a drug combination which is the sum of the effects of each individual drug, while synergy occurs when the combined effect of the drugs is greater than additive. Antagonism arises when the combined effect is less than additive (<xref rid="bibr75-02698811231211219" ref-type="bibr">Niu et al., 2019</xref>).</p><p>One common mechanism of pharmacodynamic drug interaction is competition at the receptor level. When two drugs interact with the same receptor, they can compete for binding, leading to alterations in their pharmacological effects (<xref rid="bibr62-02698811231211219" ref-type="bibr">Lambert, 2004</xref>). For instance, blocking the receptors where LSD, psilocin, mescaline or DMT exert their effects, such as 5-HT<sub>2A</sub>, could impede their psychological effects.</p><p>An example of a pharmacokinetic DDI is the inhibition of drug-metabolising enzymes, such as cytochrome P450, which are responsible for metabolising a broad range of drugs (<xref rid="bibr109-02698811231211219" ref-type="bibr">Zhao et al., 2021</xref>). Inhibition of these enzymes by concomitant drugs or circulating metabolites can lead to altered drug metabolism and impact the drug&#8217;s effects and influence treatment outcomes (<xref rid="bibr109-02698811231211219" ref-type="bibr">Zhao et al., 2021</xref>). Additionally, there is the potential for interaction with P-glycoprotein (P-gp), a membrane transporter that facilitates the efflux of various drugs and is present in the kidneys, liver, gastrointestinal tract and blood&#8211;brain barrier (<xref rid="bibr4-02698811231211219" ref-type="bibr">Amin, 2013</xref>). Similar to CYP enzymes, reducing the activity of P-gp can increase the concentration of its substrates in the blood, whereas increasing its activity can decrease the concentration, leading to inadequate therapeutic effects (<xref rid="bibr4-02698811231211219" ref-type="bibr">Amin, 2013</xref>).</p><p>For instance, CYP enzymes have a known role in LSD metabolism (<xref rid="bibr68-02698811231211219" ref-type="bibr">Luethi et al., 2019</xref>) and therefore can affect LSD&#8217;s effects (<xref rid="bibr102-02698811231211219" ref-type="bibr">Straumann et al., 2023</xref>; <xref rid="bibr103-02698811231211219" ref-type="bibr">Vizeli et al., 2021</xref>). DDIs can occur even when drugs are not taken concurrently, allowing for days or even weeks between their administration. Some drugs, like fluoxetine, have prolonged inhibitory effects on CYP activity that may persist for several weeks following its discontinuation due to the extended half-life of fluoxetine and its metabolite norfluoxetine (<xref rid="bibr53-02698811231211219" ref-type="bibr">Hemeryck and Belpaire, 2002</xref>).</p><p>Currently, there is limited literature available on the DDIs between classic psychedelics and other drugs. While two review articles have been published on this subject, the first one was limited in scope (<xref rid="bibr108-02698811231211219" ref-type="bibr">Wyatt et al., 1976</xref>) and the second one focused solely on 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin interactions with psychiatric medications (<xref rid="bibr93-02698811231211219" ref-type="bibr">Sarparast et al., 2022</xref>). To fill this gap, this systematic review aimed to provide a comprehensive overview of the current state of research on DDIs between classic psychedelics and any other drugs. We conducted a thorough literature search and reported on both physiological and subjective outcomes. This review offers valuable insights into the potential risks and benefits of combining classic psychedelics (LSD, psilocybin, mescaline, DMT and 5-MeO-DMT) with other drugs, thereby guiding researchers and clinicians in this field.</p></sec><sec sec-type="methods" id="section2-02698811231211219"><title>Methods</title><p>This review was registered in PROSPERO (CRD42022336092) and followed the latest Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (2020) guidelines (<xref rid="bibr79-02698811231211219" ref-type="bibr">Page et al., 2021</xref>). A keyword search for articles pertaining to classical psychedelics (LSD, psilocybin, mescaline, DMT and ayahuasca) was initially conducted on June 5, 2022, in three primary scientific databases: PubMed, PsycINFO and Web of Science (with no year restriction). These databases comprise a general journal articles database and a database specialised in biomedicine and psychology research. Search terms included keywords (including synonyms) related to classic psychedelics in the title, abstract, keywords, full text (where available) and MeSH terms, as well as keywords related to drug interactions, side effects and adverse reactions. The search was not limited by the time period to capture all relevant articles. A total of 2151 articles were identified during the first search. The search was repeated on September 2, 2023, resulting in the identification of 262 additional articles published since the initial search. The full search terms for each database are provided in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/02698811231211219" ext-link-type="uri">Supplemental Material S1</ext-link>. Furthermore, on September 2, 2023, an additional search was carried out using the same search parameters to identify articles detailing drug interactions involving 5-MeO-DMT (full search terms are provided in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/02698811231211219" ext-link-type="uri">Supplemental Material S2</ext-link>). A total of 507 records relating to 5-MeO-DMT were found.</p><p>Additionally, to ensure comprehensive coverage, a search was conducted in the Multidisciplinary Association for Psychedelic Studies (MAPS) comprehensive online &#8216;Psychedelic Bibliography&#8217; database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bibliography.maps.org" ext-link-type="uri">https://bibliography.maps.org</ext-link>), which contains scientific but also non-scientific articles specifically about psychedelics, dating back to 1841. At the time of the search (November 20, 2022), the database contained 13,237 records. All records were downloaded, followed by keyword searches in all titles and abstracts (targeting &#8216;LSD&#8217;, &#8216;psilocybin&#8217;, &#8216;mescaline&#8217;, &#8216;DMT&#8217; and &#8216;ayahuasca&#8217;, including synonyms and variations), resulting in a total of 6336 records.</p><p>Furthermore, we manually searched a registry of clinical trials at ClinicalTrials.gov on April 20, 2023, to find any articles containing results from clinical trials that were missed in the database search and conducted reference lists checking of included studies to find additional missing articles. An additional search of ClinicalTrials.gov was conducted on September 2, 2023 to find clinical trials involving 5-MeO-DMT.</p><p>Records were screened in three phases: first, those found via a scientific database search; second, those from the MAPS bibliography database and finally, records from a search for 5-MeO-DMT. In all cases, a systematic review application Catchii (<xref rid="bibr52-02698811231211219" ref-type="bibr">Halman and Oshlack, 2023</xref>) was used. Duplicate removal was performed using Catchii&#8217;s duplicate detection method and the results were manually verified before removal. Two researchers independently conducted title and abstract screening, both of whom were blinded to each other&#8217;s decisions. The inclusion criteria were as follows: (1) any article on human participants, (2) any article describing the usage of any classical psychedelics with another drug, (3) studies describing physiological and/or psychological effects of classical psychedelics with another drug (or the lack of), (4) studies that were either randomised controlled trials, observational studies (cohort, case&#8211;control, cross-sectional) or case reports/studies, and (5) studies published in English. Disagreements between reviewers were discussed until a consensus decision was reached. Records that did not meet the population, intervention and outcome criteria were excluded. After removing duplicates, a total of 7102 records (1667 from the first phase, 5065 from the second phase and 370 from the third phase) underwent the first stage of screening, which involved title and abstract analysis. Subsequently, the full text of the 77 reports that passed this stage was assessed in the second stage, including articles identified from citation searches. Due to the small number of records retrieved from the updated scientific database search, each title and abstract was assessed directly within the search results. The summary of results is shown on the PRISMA flow diagram (<xref rid="fig1-02698811231211219" ref-type="fig">Figure 1</xref>). Data from all eligible records were extracted by the authors of this review, who corroborated each other&#8217;s findings. Outcome measures included physiological and psychological outcomes.</p><fig position="float" id="fig1-02698811231211219" orientation="portrait"><label>Figure 1.</label><caption><p>PRISMA flow chart depicting the identification of studies in the systematic review process.</p><p>PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231211219-fig1.jpg"/></fig></sec><sec sec-type="results" id="section3-02698811231211219"><title>Results</title><p>The results of this systematic review include studies investigating DDIs between psychedelic drugs (LSD, psilocybin, mescaline, 5-MeO-DMT, DMT and ayahuasca) and other drugs. Regarding LSD, the review examined interactions with antipsychotics (chlorpromazine), mood stabilisers (lithium), various antidepressants including selective serotonin reuptake inhibitors (SSRIs; fluoxetine, sertraline, paroxetine and trazodone), tricyclic antidepressants (TCAs; imipramine, desipramine and clomipramine), as well as monoamine oxidase inhibitors (MAOIs; phenelzine, isocarboxazid, nialamide and iproniazid) and other substances (azacyclonol). Recreational substances (alcohol and MDMA), as well as other substances such as ketanserin, reserpine, niacin, scopolamine and phenoxybenzamine, were also included.</p><p>Regarding psilocybin, the review contains reports on its interactions with anxiolytics (buspirone), antipsychotics (chlorpromazine, haloperidol and risperidone), SSRI antidepressants (escitalopram) and recreational drugs (alcohol). Other investigated substances included ketanserin and ergotamine. In the case of mescaline, the review examined interactions with antipsychotics (chlorpromazine and promazine), antidepressants (azacyclonol) and the compound 2,4,5-trimethoxyphenethylamine (2C-O). For DMT, the review explored interactions with MAOI antidepressants (iproniazid), as well as other substances like racemic pindolol and methysergide. Lastly, one report of the SSRI antidepressant fluoxetine was found for ayahuasca and two case reports for 5-MeO-DMT involving the use of &#946;-carbolines.</p><p>Results of studies included in this review are provided as separate tables for LSD (<xref rid="table1-02698811231211219" ref-type="table">Table 1</xref>), psilocybin (<xref rid="table2-02698811231211219" ref-type="table">Table 2</xref>), mescaline (<xref rid="table3-02698811231211219" ref-type="table">Table 3</xref>), DMT together with ayahuasca (<xref rid="table4-02698811231211219" ref-type="table">Table 4</xref>) and 5-MeO-DMT (<xref rid="table5-02698811231211219" ref-type="table">Table 5</xref>), grouped by drug class. More detailed narrative descriptions of the results from each study are shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/02698811231211219" ext-link-type="uri">Supplemental Material S3</ext-link>. Additionally, a combined table (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/02698811231211219" ext-link-type="uri">Supplemental Table S1</ext-link>) summarises all the results from <xref rid="table1-02698811231211219" ref-type="table">Tables 1</xref> to <xref rid="table5-02698811231211219" ref-type="table">5</xref>, along with listing the potentially relevant molecular targets and actions of each drug.</p><table-wrap position="float" id="table1-02698811231211219" orientation="portrait"><label>Table 1.</label><caption><p>Summary of studies and case reports describing interactions (or the absence thereof) between LSD and other drugs.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231211219-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author and<break/>year</th><th align="left" rowspan="1" colspan="1">Study type</th><th align="left" rowspan="1" colspan="1">Drug</th><th align="left" rowspan="1" colspan="1">Dose</th><th align="left" rowspan="1" colspan="1">Participants</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<xref rid="bibr56-02698811231211219" ref-type="bibr">Isbell and Logan (1957)</xref>
</td><td rowspan="1" colspan="1">Placebo-controlled trial</td><td rowspan="1" colspan="1">Antipsychotics: chlorpromazine</td><td rowspan="1" colspan="1">(1) Pretreatment with 50&#8211;100&#8201;mg chlorpromazine 30&#8201;min prior to 40&#8211;60&#8201;&#956;g LSD.<break/>(2) Administration of 75&#8201;mg chlorpromazine at the height of 60&#8201;&#956;g LSD.<break/>(3) Administration of either 75&#8201;mg oral or 25&#8201;mg intramuscular chlorpromazine 30&#8201;min after ingestion of 60&#8211;150&#8201;&#956;g LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;6&#8211;9 (adult male drug addicts)</td><td rowspan="1" colspan="1">Pretreatment of chlorpromazine significantly reduced mental, hallucinations, visual perception distortion, anxiety and pupillary reactions to LSD.<break/>Intramuscular, but not oral, administration of chlorpromazine after ingestion of LSD significantly blocked the effects of LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr72-02698811231211219" ref-type="bibr">Murphree (1962)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Antipsychotics: chlorpromazine</td><td rowspan="1" colspan="1">Pretreatment with 25&#8201;mg chlorpromazine 30&#8201;min before ingestion of 15&#8211;20&#8201;&#956;g LSD.<break/>Co-administration of chlorpromazine with LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;18 (healthy)</td><td rowspan="1" colspan="1">Pretreatment of chlorpromazine 30&#8201;min before LSD blocked LSD effects and elevated the threshold dose. When chlorpromazine was given simultaneously or after LSD ingestion, no blocking effects were observed.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr1-02698811231211219" ref-type="bibr">Abramson et al. (1960)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Antipsychotics: chlorpromazine</td><td rowspan="1" colspan="1">Three experiments of oral administration of 50&#8201;mg chlorpromazine at 1.5&#8201;h before, after or simultaneous with 50&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;3 (healthy)</td><td rowspan="1" colspan="1">Participants who took chlorpromazine before LSD ingestion showed enhanced positive responses to LSD.<break/>Chlorpromazine ingestion after LSD also increased positive responses to LSD and reduced the usual anxiety symptoms such as sweating and moist palms. Simultaneous ingestion of chlorpromazine and LSD produced similar effects as LSD alone.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr95-02698811231211219" ref-type="bibr">Schwarz (1967)</xref>
</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">Antipsychotics: chlorpromazine</td><td rowspan="1" colspan="1">25&#8201;mg chlorpromazine was given 4&#8201;h after 100&#8201;&#956;g of LSD (intravenous).</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;2 (schizophrenic)<break/>Age: 22 and 33</td><td rowspan="1" colspan="1">Both patients reported that chlorpromazine administration increased anxiety and intensified the effects of LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy (1996)</xref>
</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">Mood stabilisers: lithium</td><td rowspan="1" colspan="1">600&#8211;1000&#8201;mg/day of lithium for 7&#8211;50&#8201;weeks prior to 200&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;3 (patients treated for depression)<break/>Age: 21&#8211;29</td><td rowspan="1" colspan="1">Participants experienced earlier onset as well as increased hallucinatory and psychological effects of LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr100-02698811231211219" ref-type="bibr">Strassman (1992)</xref>
</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">Antidepressants (SSRI): fluoxetine</td><td rowspan="1" colspan="1">20&#8201;mg/day fluoxetine; LSD dose unknown but one that produces full hallucinogenic effects.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;1 (patient for dysthymia)<break/>Age: 38</td><td rowspan="1" colspan="1">Markedly decreased sensitivity to LSD and required 2 to 3 times more than the usual dose to elicit a full hallucinogenic effect of LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr12-02698811231211219" ref-type="bibr">Bonson et al. (1996)</xref>
</td><td rowspan="1" colspan="1">Cross-sectional study</td><td rowspan="1" colspan="1">Antidepressants (SSRI): fluoxetine</td><td rowspan="1" colspan="1">Pretreatment of fluoxetine of 20&#8211;80&#8201;mg/day for 2&#8211;150&#8201;weeks followed by 250&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;18 (patients treated for depression)</td><td rowspan="1" colspan="1">Fluoxetine delayed the onset of LSD effects (8 out of 18 patients) and markedly diminished the hallucinogenic and psychological effects as well as the overall response of LSD regardless of the dose or duration of fluoxetine pretreatment.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr12-02698811231211219" ref-type="bibr">Bonson et al. (1996)</xref>
</td><td rowspan="1" colspan="1">Cross-sectional study</td><td rowspan="1" colspan="1">Antidepressants (SSRI): sertraline</td><td rowspan="1" colspan="1">Pretreatment of sertraline of 50&#8211;200&#8201;mg/day for 3&#8211;40&#8201;weeks followed by 200&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;11 (patients treated for depression)</td><td rowspan="1" colspan="1">Sertraline did not affect the onset of LSD effects. Most of the participants experienced decreased physical, hallucinogenic and psychological effects of LSD regardless of dosage or duration of sertraline treatment.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr12-02698811231211219" ref-type="bibr">Bonson et al. (1996)</xref>
</td><td rowspan="1" colspan="1">Cross-sectional study</td><td rowspan="1" colspan="1">Antidepressants (SSRI): paroxetine</td><td rowspan="1" colspan="1">Pretreatment of 20&#8211;40&#8201;mg/day paroxetine for 3&#8201;30&#8201;weeks followed by 150&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;3 (patients treated for depression)</td><td rowspan="1" colspan="1">Paroxetine pretreatment did not affect the onset of effects but attenuated the hallucinogenic as well as physiologic effects of LSD and overall, reduced responses to LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr12-02698811231211219" ref-type="bibr">Bonson et al. (1996)</xref>
</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">Antidepressants (SARI): trazodone</td><td rowspan="1" colspan="1">Pretreatment with 200&#8201;mg/day for 24&#8201;weeks followed by a &#8216;moderate&#8217; dose of LSD (no more details given).</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;1 (patient treated for depression)</td><td rowspan="1" colspan="1">No changes to the onset of LSD effects but reduced the hallucinogenic and physiological effects of LSD as well as the overall response of LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy (1996)</xref>
</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">Antidepressants (TCA): imipramine</td><td rowspan="1" colspan="1">175&#8211;200&#8201;mg/day for 8&#8211;40&#8201;weeks before the LSD dose of 80&#8211;200&#8201;&#956;g.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;2 (patients treated for depression)<break/>Age: 26&#8211;28</td><td rowspan="1" colspan="1">Patients experienced earlier onset of LSD effects and increased hallucinatory as well as psychological effects.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy (1996)</xref>
</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">Antidepressants (TCA): desipramine</td><td rowspan="1" colspan="1">200&#8201;mg/day for 100&#8211;150+&#8201;weeks before 100&#8211;150&#8201;&#956;g of LSD dose.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;2 (patients treated for depression)<break/>Age: 27&#8211;32</td><td rowspan="1" colspan="1">Patients experienced earlier onset of LSD effects and increased hallucinatory as well as psychological effects.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy (1996)</xref>
</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">Antidepressants (TCA): clomipramine</td><td rowspan="1" colspan="1">125&#8201;mg/day for 12&#8201;weeks before a &#8216;moderate&#8217; dose of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;1 (patient treated for alcoholism)<break/>Age: 25</td><td rowspan="1" colspan="1">The patient experienced an earlier onset of LSD effect, increased physical and hallucinatory as well as psychological effects.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy (1996)</xref>
</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">Antidepressants (MAOI): phenelzine</td><td rowspan="1" colspan="1">60&#8211;75&#8201;mg/day for 12&#8201;weeks before 150&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;2 (patients treated for depression)</td><td rowspan="1" colspan="1">No change to the onset of LSD effects but nearly abolished the subjective responses of LSD including hallucination and psychological effects</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr85-02698811231211219" ref-type="bibr">Resnick et al. (1964)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Antidepressants (MAOI): isocarboxazid</td><td rowspan="1" colspan="1">Pretreatment with 30&#8201;mg/day isocarboxazid for 5&#8201;days or 2&#8201;weeks before 40&#8201;&#956;g of oral ingestion of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;4 (healthy)</td><td rowspan="1" colspan="1">Isocarboxazid pretreatment attenuated psychological, autonomic and neurologic responses of LSD including blood pressure, heart rate, sensory and motor functions.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr47-02698811231211219" ref-type="bibr">Grof and Dytrych (1965)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Antidepressants (MAOI): nialamide</td><td rowspan="1" colspan="1">250&#8211;500&#8201;mg/day of parenteral administration of nialamide for several days, followed by 150&#8211;300&#8201;mg/day peroral application of nialamide, and then 150&#8201;&#956;g of LSD on test day.<break/>Pretreatment of nialamide daily for 3&#8201;weeks to reach a total dose of 3500&#8201;mg, followed by 150 and 500&#8201;&#956;g of LSD on test day.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;14 (neurotic patients)</td><td rowspan="1" colspan="1">Premedication with nialamide blocked reactions to LSD and patients were able to tolerate 150 and 500&#8201;&#956;g of LSD without clinical or psychotic reactions/symptoms of LSD and minimal subjective complaints.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr27-02698811231211219" ref-type="bibr">DeMaar et al. (1960)</xref>
</td><td rowspan="1" colspan="1">Placebo-controlled trial</td><td rowspan="1" colspan="1">Antidepressants (MAOI): iproniazid</td><td rowspan="1" colspan="1">100&#8201;mg iproniazid with LSD in doses of 25, 50 and 100&#8201;&#956;g.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;16 (healthy)</td><td rowspan="1" colspan="1">No change to the physical or subjective effects of LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr37-02698811231211219" ref-type="bibr">Fabing (1955)</xref>
</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">Antidepressants: azacyclonol</td><td rowspan="1" colspan="1">(1) Pretreatment with 10&#8211;30&#8201;mg azacyclonol for 1&#8201;week before ingestion of 100&#8201;&#956;g LSD.<break/>(2) Pretreatment of participants with a total of four doses of 50&#8201;mg azacyclonol at 50, 38, 26 and 2&#8201;h before ingestion of 100&#8201;&#956;g LSD.<break/>(3) Premedication with azacyclonol at either 5 or 10&#8201;mg twice daily for 7&#8201;days, followed by ingestion of 100&#8201;&#956;g LSD. Five weeks later, participants received the same dose of LSD again without azacyclonol premedication.</td><td rowspan="1" colspan="1">(1) <italic toggle="yes">N</italic>&#8201;=&#8201;6 (healthy)<break/>Age: 19&#8211;40<break/>(2) <italic toggle="yes">N</italic>&#8201;=&#8201;2<break/>(3) <italic toggle="yes">N</italic>&#8201;=&#8201;2</td><td rowspan="1" colspan="1">(1) Azacyclonol pretreatment reduced the psychological effects of LSD but had no effect on the physical effects of LSD.<break/>(2) The hallucinogenic effects of LSD were abolished by pretreatment of azacyclonol 50&#8201;h before ingestion of LSD. Other neurological effects like attention deficit or physiological effects like nausea or tight sensations were still experienced by the participants<break/>(3) Premedication of azacyclonol for 7&#8201;days, followed by a 5-week washout did not block the effects of LSD. One subject was administered 40&#8201;mg azacyclonol intravenously at the fifth hour post-LSD ingestion, reported decreased anxiety and decreased psychological effects.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr26-02698811231211219" ref-type="bibr">Clark (1956)</xref>
</td><td rowspan="1" colspan="1">Placebo-controlled trial</td><td rowspan="1" colspan="1">Antidepressants: azacyclonol</td><td rowspan="1" colspan="1">(1) Pretreatment with azacyclonol for 10&#8211;40&#8201;mg for 2&#8211;5&#8201;days, followed by 100&#8201;&#956;g LSD.<break/>(2) Intravenous injection of 100&#8201;mg azacyclonol was administered after 100&#8201;&#956;g LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;5 (schizophrenic patients)</td><td rowspan="1" colspan="1">(1) No evidence of LSD-blocking effects by azacyclonol was observed.<break/>(2) No evidence of azacyclonol effects in changing the effects of LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr56-02698811231211219" ref-type="bibr">Isbell and Logan (1957)</xref>
</td><td rowspan="1" colspan="1">Placebo-controlled trial</td><td rowspan="1" colspan="1">Antidepressants: azacyclonol</td><td rowspan="1" colspan="1">Pretreatment with 20&#8201;mg of oral azacyclonol for 7&#8201;days and an additional 20&#8201;mg 2&#8201;h before administration of 60&#8201;&#956;g LSD. An additional dose of 40&#8201;mg was given intravenously 3&#8201;h after LSD administration.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;12</td><td rowspan="1" colspan="1">No reduction of any aspect of the LSD reaction was observed from the blocking experiment. No significant diminution in any aspect of the LSD reaction could be observed after azacyclonol administration.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr9-02698811231211219" ref-type="bibr">Barrett et al. (2000)</xref>
</td><td rowspan="1" colspan="1">Cross-sectional study</td><td rowspan="1" colspan="1">Recreational: alcohol</td><td rowspan="1" colspan="1">Self-report study. Ingestion of alcohol concurrent with the administration of LSD (no more details given).</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;22<break/>Age: 18&#8211;28&#8201;years</td><td rowspan="1" colspan="1">Ingestion of LSD concurrent with alcohol consumption diminished the effects of alcohol. No differences in the subjective effects of LSD were associated with alcohol use.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr102-02698811231211219" ref-type="bibr">Straumann et al. (2023)</xref>
</td><td rowspan="1" colspan="1">Placebo-controlled trial</td><td rowspan="1" colspan="1">Recreational: MDMA</td><td rowspan="1" colspan="1">Co-administration of 100&#8201;&#956;g LSD and 100&#8201;mg MDMA.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;24 (healthy)<break/>Age: 25&#8211;54&#8201;years</td><td rowspan="1" colspan="1">Co-administration of MDMA and LSD resulted in a longer psychedelic experience than with LSD alone (average of 1.5&#8201;h). There were no significant differences in subjective effects, as measured by Visual Analog Scales, 5 Dimensions of Altered States of Consciousness, Mystical Experience Questionnaire and Altered States of Consciousness Rating Scale, compared to LSD alone. Increased blood pressure and heart rate compared to LSD alone.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr83-02698811231211219" ref-type="bibr">Preller et al. (2018)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Other: ketanserin</td><td rowspan="1" colspan="1">Pretreatment with 40&#8201;mg ketanserin 60&#8201;min before treatment with 100&#8201;&#956;g LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;24 (healthy)</td><td rowspan="1" colspan="1">Ketanserin fully blocked the subjective and mental effects of LSD, reduced communication among brain areas involved in planning and decision-making (fMRI and BOLD).</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr76-02698811231211219" ref-type="bibr">Olbrich et al. (2021)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Other: ketanserin</td><td rowspan="1" colspan="1">Pretreatment with 40&#8201;mg ketanserin 60&#8201;min before treatment with 100&#8201;&#956;g LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;17 (healthy)</td><td rowspan="1" colspan="1">Ketanserin pretreatment shifted participants on LSD towards parasympathetic activity which is associated with less intense subjective experience including less audio-visual synaesthesia, 5D-ASC elementary imagery and experience of unity.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr55-02698811231211219" ref-type="bibr">Holze et al. (2021)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Other: ketanserin</td><td rowspan="1" colspan="1">Pretreatment with 40&#8201;mg ketanserin 60&#8201;min before treatment with 200&#8201;&#956;g LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;16 (healthy)</td><td rowspan="1" colspan="1">Ketanserin pretreatment followed by a high dose of LSD at 200&#8201;&#956;g blocked subjective drug effects, ego dissolution, anxiety and oceanic boundlessness score to levels that were similar to a 25&#8201;&#956;g LSD dose. Physical effects such as blood pressure and body temperature induced by 200&#8201;&#956;g LSD&#8201;+&#8201;ketanserin were comparable to placebo controls.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr11-02698811231211219" ref-type="bibr">Becker et al. (2023)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Other: ketanserin</td><td rowspan="1" colspan="1">Oral administration of 40&#8201;mg ketanserin 60&#8201;min after ingestion of 100&#8201;&#956;g LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;24 (healthy)</td><td rowspan="1" colspan="1">Administration of ketanserin after the effects of LSD has reversed subjective and autonomic responses to LSD in humans. Duration of LSD effects was reduced from 8.5&#8201;h to 3.5&#8201;h (~60%) by ketanserin. Ketanserin did not alter overall mystical experiences or reverse the LSD-induced increase of plasma BDNF, or alter the pharmacokinetics of LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr86-02698811231211219" ref-type="bibr">Resnick et al. (1965)</xref>
</td><td rowspan="1" colspan="1">Placebo-controlled trial</td><td rowspan="1" colspan="1">Other: reserpine</td><td rowspan="1" colspan="1">Pretreatment with 0.5&#8201;mg/day reserpine for 2&#8201;weeks before ingestion of 75&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;3 (healthy)</td><td rowspan="1" colspan="1">Pretreatment with reserpine enhanced the effects of LSD on autonomic and neurologic responses as well as psychological reactions to LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr56-02698811231211219" ref-type="bibr">Isbell and Logan (1957)</xref>
</td><td rowspan="1" colspan="1">Placebo-controlled trial</td><td rowspan="1" colspan="1">Other: reserpine</td><td rowspan="1" colspan="1">Pretreatment with either 2.5&#8201;mg oral or 2&#8201;mg intramuscular reserpine 2, 10 and 22&#8201;h prior to administration of 60&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;12 (non-psychotic drug addicts)</td><td rowspan="1" colspan="1">Reserpine intensified LSD effects of nervousness and confusion, including nasal stuffiness, nausea, diarrhoea, vomiting and lethargy in a dose-dependent manner. Participants who underwent intramuscular administration of reserpine reported intensified LSD effects.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr41-02698811231211219" ref-type="bibr">Freedman (1963)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Other: reserpine</td><td rowspan="1" colspan="1">Pretreatment with a single dose of 10&#8201;mg reserpine 2&#8201;days prior to 120&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;14 (schizophrenic females)</td><td rowspan="1" colspan="1">Reserpine enhanced the physical effects of LSD including prolonged tremors and akathisia, effects were &#8216;unpleasant&#8217; and lasted longer.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr2-02698811231211219" ref-type="bibr">Agnew and Hoffer (1955)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Other: niacin</td><td rowspan="1" colspan="1">Pretreatment with 3&#8201;g of oral niacin for 3&#8201;days prior to 100&#8201;&#956;g of LSD ingestion on test day.<break/>Intravenous injection of 0.2&#8201;g niacin post-LSD ingestion (100&#8201;&#956;g) at the height of LSD effects.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;10 (healthy males)<break/>Age: 19&#8211;31, mean of 26&#8201;years</td><td rowspan="1" colspan="1">Pretreatment with niacin delayed the onset of LSD effects and prevented most of the perceptual changes from occurring.<break/>Niacin administration post-LSD ingestion attenuated all effects of LSD within 5&#8201;min and markedly diminished the proprioceptive, perceptual, cognitive and motor effects of LSD.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr57-02698811231211219" ref-type="bibr">Isbell et al. (1959)</xref>
</td><td rowspan="1" colspan="1">Placebo-controlled trial</td><td rowspan="1" colspan="1">Other: scopolamine</td><td rowspan="1" colspan="1">Subjects were administered with either of the following four different doses of scopolamine at 0.42, 0.64, 0.85 and 1.3&#8201;mg followed by simultaneous administration of 60&#8201;&#956;g of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;12</td><td rowspan="1" colspan="1">Scopolamine did not alter LSD-induced effects on patellar reflex, pupil size, blood pressure or subjective clinical effects.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr57-02698811231211219" ref-type="bibr">Isbell et al. (1959)</xref>
</td><td rowspan="1" colspan="1">Placebo-controlled trial</td><td rowspan="1" colspan="1">Other: phenoxybenzamine</td><td rowspan="1" colspan="1">Ten patients received 0.5, 1.0, and 1.0&#8201;mg/kg. of phenoxybenzamine hydrochloride 24, 11, and 2&#8201;hours prior to administration of 1.0&#8201;&#956;g/kg. of LSD.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;10</td><td rowspan="1" colspan="1">None of the doses of phenoxybenzamine pretreatment did alter LSD-induced effects on pulse rate, blood pressure or subjective clinical effects.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-02698811231211219"><p>5D-ASC: 5-dimensional altered states of consciousness; BOLD: blood-oxygen-level-dependent; fMRI: functional magnetic resonance imaging; LSD: lysergic acid diethylamide; MAOI: monoamine oxidase inhibitor; MDMA: 3,4-methylenedioxymethamphetamine; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table2-02698811231211219" orientation="portrait"><label>Table 2.</label><caption><p>Summary of studies and case reports describing interactions (or the absence thereof) between psilocybin and other drugs.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231211219-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author and year</th><th align="left" rowspan="1" colspan="1">Study type</th><th align="left" rowspan="1" colspan="1">Drug</th><th align="left" rowspan="1" colspan="1">Dose</th><th align="left" rowspan="1" colspan="1">Participants</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<xref rid="bibr82-02698811231211219" ref-type="bibr">Pokorny et al. (2016)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Anxiolytics: buspirone</td><td rowspan="1" colspan="1">Pretreatment with 20&#8201;mg oral buspirone 60&#8201;min before oral administration of 0.17&#8201;mg/kg psilocybin.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;19 (healthy)</td><td rowspan="1" colspan="1">Buspirone pretreatment markedly reduced psilocybin-induced visual perception distortion.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr60-02698811231211219" ref-type="bibr">Keeler (1967)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Antipsychotics: chlorpromazine</td><td rowspan="1" colspan="1">Pretreatment with 50&#8201;mg chlorpromazine 2&#8201;h before 0.2&#8201;mg/kg psilocybin.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;8 (healthy)</td><td rowspan="1" colspan="1">Pretreatment with chlorpromazine significantly decreased psilocybin-induced pupil dilation and visual perception distortion.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr105-02698811231211219" ref-type="bibr">F. X. Vollenweider et al. (1998)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Antipsychotics: haloperidol</td><td rowspan="1" colspan="1">Pretreatment with intravenous 0.021&#8201;mg/kg haloperidol 75&#8201;min before oral administration of 0.25&#8201;mg/kg psilocybin.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;15 (healthy)</td><td rowspan="1" colspan="1">Haloperidol pretreatment reduced psilocybin effects on the Oceanic boundlessness, measures of derealisation and depersonalisation phenomena but increased anxiety without any effects on visual hallucinations or delayed response tasks.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr105-02698811231211219" ref-type="bibr">F. X. Vollenweider et al. (1998)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Antipsychotics: risperidone</td><td rowspan="1" colspan="1">Pretreatment with either 0.5&#8201;mg or 1&#8201;mg oral risperidone 90&#8201;min before oral administration of 0.25&#8201;mg/kg psilocybin.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;15 (healthy)</td><td rowspan="1" colspan="1">Risperidone pretreatment attenuated the effects of psilocybin in a dose-dependent manner.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr10-02698811231211219" ref-type="bibr">Becker et al. (2022)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Antidepressants (SSRI): escitalopram</td><td rowspan="1" colspan="1">Pretreatment with 10&#8201;mg/day for 7&#8201;days, followed by 20&#8201;mg/day for 7&#8201;days, and a single dose on test day 2&#8201;h before 25&#8201;mg psilocybin treatment.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;23 (healthy)</td><td rowspan="1" colspan="1">Escitolopram pretreatment reduced the negative acute effects of psilocybin (subjective bad drug effects, anxious-ego dissolution, anxiety and &#8220;nadir effects&#8221;). The positive mood and mind-altering effects of a full dose of psilocybin were not reduced by pretreatment.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr105-02698811231211219" ref-type="bibr">F. X. Vollenweider et al. (1998)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Other: ketanserin</td><td rowspan="1" colspan="1">Pretreatment with either 20 or 40&#8201;mg oral ketanserin 75&#8201;min before oral administration of 0.25&#8201;mg/kg psilocybin.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;27 (healthy)<break/>Age: mean 29.7</td><td rowspan="1" colspan="1">Ketanserin pretreatment blocked psilocybin effects in a dose-dependent manner on the delayed response task and Altered State of Consciousness Rating scale.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr23-02698811231211219" ref-type="bibr">Carter et al. (2005)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Other: ketanserin</td><td rowspan="1" colspan="1">Pretreatment with 50&#8201;mg oral ketanserin 90&#8201;min before oral administration of 0.215&#8201;mg/kg psilocybin.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;8 (healthy)</td><td rowspan="1" colspan="1">Ketanserin pretreatment blocked the subjective effects of psilocybin based on the 5D-ASC rating scale (anxious ego dissolution, euphoria, depersonalisation and hallucination). Ketanserin did not rescue psilocybin-induced impairment in attentional tracking performance.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr24-02698811231211219" ref-type="bibr">Carter et al. (2007)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Other: ketanserin</td><td rowspan="1" colspan="1">Pretreatment with 50&#8201;mg oral ketanserin 90&#8201;min before oral administration of 0.215&#8201;mg/kg psilocybin.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;10 (healthy)</td><td rowspan="1" colspan="1">Ketanserin pretreatment blocked the subjective effects on the 5D-ASC rating scale (anxious ego dissolution, depersonalisation, euphoria and hallucination) but did not influence either the psilocybin-induced slowing of binocular rivalry or negative drug symptoms (alertness and arousal).</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr82-02698811231211219" ref-type="bibr">Pokorny et al. (2016)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Other: ergotamine</td><td rowspan="1" colspan="1">Pretreatment with 3&#8201;mg oral ergotamine 100&#8201;min before oral administration of 0.17&#8201;mg/kg psilocybin.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;17 (healthy)</td><td rowspan="1" colspan="1">Ergotamine did not significantly alter subjective experiences (5D-ASC scores).</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr9-02698811231211219" ref-type="bibr">Barrett et al. (2000)</xref>
</td><td rowspan="1" colspan="1">Cross-sectional study</td><td rowspan="1" colspan="1">Recreational: alcohol</td><td rowspan="1" colspan="1">Non-intoxicating levels of alcohol consumed either before or after psilocybin (self-reported, doses unknown).</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;15</td><td rowspan="1" colspan="1">The subjective effects of alcohol are antagonised by psilocybin, but the subjective effects of psilocybin were diminished in only 2 (out of 15) participants while only 1 reported enhanced effects, the rest (80%) reported unchanged effects.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-02698811231211219"><p>5D-ASC: 5-dimensional altered states of consciousness; SSRI: selective serotonin reuptake inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table3-02698811231211219" orientation="portrait"><label>Table 3.</label><caption><p>Summary of studies and case reports describing interactions (or the absence thereof) between mescaline and other drugs.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231211219-table3.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author and year</th><th align="left" rowspan="1" colspan="1">Study type</th><th align="left" rowspan="1" colspan="1">Drug</th><th align="left" rowspan="1" colspan="1">Dose</th><th align="left" rowspan="1" colspan="1">Participants</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<xref rid="bibr64-02698811231211219" ref-type="bibr">Lesse (1958)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Antipsychotics: chlorpromazine and promazine</td><td rowspan="1" colspan="1">Mescaline (intravenous) or LSD (oral) followed by intravenous chlorpromazine or promazine (no more details given).</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;25 (patients with schizophrenia)</td><td rowspan="1" colspan="1">The administration of chlorpromazine or promazine led to a reduction in acute anxiety symptoms in 68% (17/25) of participants.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr37-02698811231211219" ref-type="bibr">Fabing (1955)</xref>
</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">Antidepressants: azacyclonol</td><td rowspan="1" colspan="1">(1) Pretreatment with 50&#8201;mg azacyclonol at 50, 38, 26 and 2&#8201;h before ingestion of 400&#8201;mg mescaline sulphate.<break/>2) Placebo instead of pretreatment, at 4.5 or 5&#8201;h mark 100&#8201;mg azacyclonol (intravenous).</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;4 (healthy) Age: 20&#8211;45</td><td rowspan="1" colspan="1">(1) Pretreatment with azacyclonol likely attenuated the effects of mescaline.<break/>(2) Azacyclonol treatment during the height of the experience started to block the actions of mescaline.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr26-02698811231211219" ref-type="bibr">Clark (1956)</xref>
</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">Antidepressants: azacyclonol</td><td rowspan="1" colspan="1">40&#8201;mg azacyclonol four times a day for 3&#8201;days before ingesting 200&#8201;mg and 400&#8201;mg mescaline sulphate.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;1 (healthy)</td><td rowspan="1" colspan="1">No differences in mescaline intoxication when ingesting it with or without azacyclonol pretreatment.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr30-02698811231211219" ref-type="bibr">Dittrich (1971)</xref>
</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">Other: 2C-O</td><td rowspan="1" colspan="1">Pretreatment with 100&#8211;200&#8201;mg 2C-O and 45&#8201;min later 100&#8201;mg mescaline.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;1 (healthy) Age: 29</td><td rowspan="1" colspan="1">Pretreatment with 2C-O potentiated the effects of mescaline as the ability to concentrate decreased and the time taking a test increased.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-02698811231211219"><p>LSD: lysergic acid diethylamide; 2C-O: 2,4,5-trimethoxyphenethylamine.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table4-02698811231211219" orientation="portrait"><label>Table 4.</label><caption><p>Summary of studies and case reports describing interactions (or the absence thereof) between DMT, ayahuasca and other drugs.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231211219-table4.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author and year</th><th align="left" rowspan="1" colspan="1">Study type</th><th align="left" rowspan="1" colspan="1">Drug</th><th align="left" rowspan="1" colspan="1">Dose</th><th align="left" rowspan="1" colspan="1">Participants</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<xref rid="bibr91-02698811231211219" ref-type="bibr">Sai Halasz (1963)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Antidepressants (MAOI): iproniazid</td><td rowspan="1" colspan="1">Pretreated with iproniazid (4&#8201;days 100&#8201;mg/daily) followed by a pause of 2&#8201;days. On the following day: five volunteers received a dose of 0.65&#8211;0.83&#8201;mg/kg DMT and two individuals a lower dose of 0.35&#8211;0.55&#8201;mg/kg DMT.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;7 (healthy)<break/>Age: 21&#8211;36&#8201;years<break/>4 males/3 females</td><td rowspan="1" colspan="1">Volunteers who received the lower dose of DMT did not experience hallucinations or disruptions in time and space orientation but reported an &#8216;odd&#8217; feeling. The five receiving the higher dose experienced less intense DMT effects lasting for 14&#8211;24&#8201;min.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr101-02698811231211219" ref-type="bibr">Strassman (1996)</xref>
</td><td rowspan="1" colspan="1">Randomised, placebo-controlled trial</td><td rowspan="1" colspan="1">Other: racemic pindolol</td><td rowspan="1" colspan="1">Racemic pindolol (30&#8201;mg oral) and 0.1&#8201;mg/kg DMT (intravenous)</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;12 (healthy)</td><td rowspan="1" colspan="1">Pindolol pre-treatment enhanced DMT effects by 2&#8211;3&#8201;times. Significant enhancement in 4&#8211;6 clinical clusters in the hallucinogen rating scale. Mean arterial blood pressure effects were enhanced, heart rate responses were blunted, prolactin responses were reduced.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr90-02698811231211219" ref-type="bibr">Sai-Halasz (1962)</xref>
</td><td rowspan="1" colspan="1">Controlled trial</td><td rowspan="1" colspan="1">Other: methysergide</td><td rowspan="1" colspan="1">Methysergide administered:<break/>1) 1&#8211;2&#8201;mg perorally 30&#8211;40&#8201;min before DMT;<break/>2) 0.5&#8201;mg intramuscularly 10&#8201;min before DMT.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;15 (healthy)</td><td rowspan="1" colspan="1">Intensification of DMT subjective effects when taken with methysergide.<break/>(1) Two individuals: heightened subjective effects of DMT; five individuals: very intense aggravation of DMT subjective effects.<break/>(2) Four individuals who took 65&#8211;80% less DMT than their first time experienced similar effects. Four individuals who took 50&#8211;60% of their first-time dose did not experience a more pronounced hallucinatory state than their first experience, and in one case, the effects were even less pronounced.</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr19-02698811231211219" ref-type="bibr">Callaway and Grob (1998)</xref>
</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">Antidepressants (SSRI): fluoxetine</td><td rowspan="1" colspan="1">Fluoxetine (20&#8201;mg/day) treatment, administration of ~100&#8201;ml ayahuasca brew.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;1<break/>36-year-old male with mild depression</td><td rowspan="1" colspan="1">Adverse effects are similar to serotonin toxicity (sweating, shivering, tremors, confusion, severe nausea, vomiting and disorientation) after consumption of ayahuasca brew that lasted for 4&#8201;h.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn4-02698811231211219"><p>DMT: N,N-dimethyltryptamine; MAOI: monoamine oxidase inhibitor; SSRI: selective serotonin reuptake inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table5-02698811231211219" orientation="portrait"><label>Table 5.</label><caption><p>Summary of studies and case reports describing interactions (or the absence thereof) between 5-MeO-DMT and other drugs.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_02698811231211219-table5.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author and year</th><th align="left" rowspan="1" colspan="1">Study type</th><th align="left" rowspan="1" colspan="1">Drug</th><th align="left" rowspan="1" colspan="1">Dose</th><th align="left" rowspan="1" colspan="1">Participants</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<xref rid="bibr17-02698811231211219" ref-type="bibr">Brush et al. (2004)</xref>
</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">Other: &#946;-carbolines</td><td rowspan="1" colspan="1">Co-administration of three Syrian rue seeds extract and 10&#8201;mg (smoked)&#8201;+&#8201;15&#8211;20&#8201;mg (snorted) of 5-MeO-DMT.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;1<break/>17-year-old male</td><td rowspan="1" colspan="1">Severe agitation, hallucinations, emesis, rhabdomyolysis, diaphoretic skin, hyperthermia (40.7&#8201;&#176;C) and tachycardia (186&#8201;bpm).</td></tr><tr><td rowspan="1" colspan="1">
<xref rid="bibr97-02698811231211219" ref-type="bibr">Sklerov et al. (2005)</xref>
</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">Other: &#946;-carbolines</td><td rowspan="1" colspan="1">Unknown composition and quantity of an herbal/synthetic combination, likely containing 5-MeO-DMT (potentially synthetic), DMT and &#946;-carbolines.</td><td rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;1<break/>25-year-old male</td><td rowspan="1" colspan="1">The subject consumed some type of &#8216;herbal tonic&#8217; before going to sleep and was found dead the next morning. Autopsy and toxicology examination reported high concentrations of DMT, 5-MeO-DMT, tetrahydroharmine, harmaline and harmine in tissues and biological fluids including liver and blood.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn5-02698811231211219"><p>DMT: N,N-dimethyltryptamine; 5-MeO-DMT: 5-methoxy-N,N-dimethyltryptamine.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="section4-02698811231211219"><title>Discussion</title><p>In this systematic review, a total of 7102 records were screened and 36 reports from 52 studies were included, providing information about the potential DDIs (or the lack of) of classic psychedelics in the scientific literature. Considering the scarcity of studies addressing DDIs involving classic psychedelics, case reports were included to provide more insights into DDIs. Although anecdotal in nature, these case reports highlight potential DDIs and areas for future research. In the following sections, all drugs are discussed, grouped by their properties and/or class, where possible. Groups with blocking or reduced effects on psychedelics are generally addressed first, followed by those with potentiating effects, and concluding with those that have mixed evidence or no effects.</p><sec id="section5-02698811231211219"><title>Serotonin 2A receptor antagonists</title><p>Classic psychedelics are known to bind to 5-HT<sub>2A</sub> receptors where it is thought that their hallucinogenic properties are mediated (<xref rid="bibr104-02698811231211219" ref-type="bibr">Vollenweider and Smallridge, 2022</xref>). The results of multiple studies on drugs that are 5-HT<sub>2A</sub> receptor antagonists, such as ketanserin, trazodone, risperidone and chlorpromazine, indicated that they were all effective in attenuating the effects of LSD and psilocybin. Specifically, ketanserin, a 5-HT<sub>2A</sub> antagonist with a strong affinity (<xref rid="bibr11-02698811231211219" ref-type="bibr">Becker et al., 2023</xref>) was found in all studies to either fully block or reduce the subjective effects of LSD (<xref rid="bibr11-02698811231211219" ref-type="bibr">Becker et al., 2023</xref>; <xref rid="bibr55-02698811231211219" ref-type="bibr">Holze et al., 2021</xref>; <xref rid="bibr76-02698811231211219" ref-type="bibr">Olbrich et al., 2021</xref>; <xref rid="bibr83-02698811231211219" ref-type="bibr">Preller et al., 2018</xref>) and psilocybin (<xref rid="bibr23-02698811231211219" ref-type="bibr">Carter et al., 2005</xref>, <xref rid="bibr24-02698811231211219" ref-type="bibr">2007</xref>; <xref rid="bibr105-02698811231211219" ref-type="bibr">F. X. Vollenweider et al., 1998</xref>). Similarly, decreased physical effects were also observed, including lowered blood pressure, body temperature and heart rate (<xref rid="bibr55-02698811231211219" ref-type="bibr">Holze et al., 2021</xref>). Similarly, <bold>risperidone</bold>, a 5-HT<sub>2A</sub> but also D<sub>2</sub> antagonist was found to attenuate the effects of psilocybin in a dose-dependent manner (<xref rid="bibr105-02698811231211219" ref-type="bibr">F. X. Vollenweider et al., 1998</xref>). <bold>Trazodone</bold>, another 5-HT<sub>2A</sub> antagonist (<xref rid="bibr7-02698811231211219" ref-type="bibr">Balsara et al., 2005</xref>), was shown to reduce the psychological and hallucinogenic effects of LSD in one case report (<xref rid="bibr12-02698811231211219" ref-type="bibr">Bonson et al., 1996</xref>).</p><p>The findings from studies using chlorpromazine, which is also a 5-HT<sub>2A</sub> receptor antagonist but has an affinity for D<sub>2</sub> and adrenoceptor &#945;<sub>1A</sub> and &#945;<sub>1B</sub> subtypes as well (<xref rid="bibr14-02698811231211219" ref-type="bibr">Boyd-Kimball et al., 2019</xref>; <xref rid="bibr42-02698811231211219" ref-type="bibr">Gillman, 1999</xref>), are inconsistent. While two studies (<xref rid="bibr56-02698811231211219" ref-type="bibr">Isbell and Logan, 1957</xref>; <xref rid="bibr72-02698811231211219" ref-type="bibr">Murphree, 1962</xref>) found that chlorpromazine reduced the intensity of LSD-induced effects as well as anxiety, another two independent studies (<xref rid="bibr1-02698811231211219" ref-type="bibr">Abramson et al., 1960</xref>; <xref rid="bibr95-02698811231211219" ref-type="bibr">Schwarz, 1967</xref>) reported the opposite. In addition, while <xref rid="bibr56-02698811231211219" ref-type="bibr">Isbell and Logan (1957)</xref> reported that oral pre-administration of chlorpromazine blocked the effects of LSD and not post-administration, then <xref rid="bibr1-02698811231211219" ref-type="bibr">Abramson et al. (1960)</xref> observed enhanced effects regardless of whether it was administered before or after LSD intake. However, the inconsistent findings regarding the effects of chlorpromazine on LSD response may be due to differences in study design, dosing regimens and individual variability. Moreover, chlorpromazine was reported to attenuate the effects of psilocybin and mescaline, where its pretreatment significantly decreased psilocybin-induced visual perception distortion (<xref rid="bibr60-02698811231211219" ref-type="bibr">Keeler, 1967</xref>) and abolished the increased anxiety observed in schizophrenic patients following mescaline ingestion (<xref rid="bibr64-02698811231211219" ref-type="bibr">Lesse, 1958</xref>). Overall, considering the available evidence, treatment with potent 5-HT<sub>2A</sub> antagonists, including medicines, is anticipated to diminish the effects of psychedelics (e.g. antipsychotics risperidone, olanzapine and pipamperone, antidepressants mirtazapine, mianserin and etoperidone as well as migraine prevention drug pizotifen).</p></sec><sec id="section6-02698811231211219"><title>Serotonin 1A receptor agonists</title><p>Pretreatment with buspirone, which is a 5-HT<sub>1A</sub> partial agonist, markedly reduced the psilocybin-induced visual hallucinations (<xref rid="bibr82-02698811231211219" ref-type="bibr">Pokorny et al., 2016</xref>). On the contrary, agonism of 5-HT<sub>1A</sub> with ergotamine did not affect any of the psilocybin effects (<xref rid="bibr82-02698811231211219" ref-type="bibr">Pokorny et al., 2016</xref>). However, given that ergotamine has lower efficacy at receptor signal transduction when compared to buspirone and its generally low bioavailability, it was suggested that the administered dose may not have been high enough to compete with psilocybin at those receptor site (<xref rid="bibr82-02698811231211219" ref-type="bibr">Pokorny et al., 2016</xref>). These findings indicate that 5-HT<sub>1A</sub> receptors may be also involved in the manifestation of psilocybin-induced effects such as visual hallucinations, affective alterations, derealisation and depersonalisation. The mechanism of action by which buspirone reduces hallucinations may involve direct stimulation of 5-HT<sub>1A</sub> receptors, or alternatively, interaction between 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors on pyramidal cells due to co-expression of 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors in cortical and visual areas (<xref rid="bibr82-02698811231211219" ref-type="bibr">Pokorny et al., 2016</xref>). Despite both psilocin and buspirone being partial agonists at 5-HT<sub>1A</sub> receptors, the blocking effect of buspirone may be due to a more effective inhibitory impact on pyramidal neurons compared to psilocin (<xref rid="bibr82-02698811231211219" ref-type="bibr">Pokorny et al., 2016</xref>).</p></sec><sec id="section7-02698811231211219"><title>Dopamine receptor antagonists</title><p>Buspirone is also an antagonist for dopamine D<sub>2</sub> receptors (low affinity) and has shown weak affinity to the 5-HT<sub>2</sub> receptors (<xref rid="bibr66-02698811231211219" ref-type="bibr">Loane and Politis, 2012</xref>), which could have a role in modulating the effects of psilocybin as well. However, while LSD is known to have an effect on the dopaminergic system (found to be important in perceived selfhood and cognition) (<xref rid="bibr63-02698811231211219" ref-type="bibr">Lawn et al., 2022</xref>) and it has a high affinity for both D<sub>1</sub> and D<sub>2</sub> receptors (<xref rid="bibr50-02698811231211219" ref-type="bibr">Halberstadt and Geyer, 2011</xref>), then psilocin does not bind to dopamine receptors (<xref rid="bibr50-02698811231211219" ref-type="bibr">Halberstadt and Geyer, 2011</xref>). Moreover, D<sub>2</sub> antagonism by haloperidol alone did not have an effect on psilocybin-induced hallucinations (<xref rid="bibr105-02698811231211219" ref-type="bibr">F. X. Vollenweider et al., 1998</xref>). Haloperidol did, however, diminish the feelings of oceanic boundlessness and derealisation and also increased anxiety (<xref rid="bibr105-02698811231211219" ref-type="bibr">F. X. Vollenweider et al., 1998</xref>). In this case, psilocybin may exert an indirect impact on dopaminergic systems, which is subsequently counteracted by haloperidol (<xref rid="bibr105-02698811231211219" ref-type="bibr">F. X. Vollenweider et al., 1998</xref>). It has been shown in rats that psilocybin administration can increase extracellular dopamine levels in the frontal cortex (<xref rid="bibr107-02698811231211219" ref-type="bibr">Wojtas et al., 2022</xref>) and psilocin administration has also increased dopamine levels in the nucleus accumbens (<xref rid="bibr92-02698811231211219" ref-type="bibr">Sakashita et al., 2015</xref>).</p></sec><sec id="section8-02698811231211219"><title>Serotonin reuptake inhibitors</title><p>Interestingly, the blocking of serotonin reuptake transporters with SSRIs, such as fluoxetine, sertraline and paroxetine, reduced the effects of LSD as reported in one study (<xref rid="bibr12-02698811231211219" ref-type="bibr">Bonson et al., 1996</xref>). Moreover, fluoxetine also delayed the onset of LSD effects in nearly half of the participants in the same study (<xref rid="bibr12-02698811231211219" ref-type="bibr">Bonson et al., 1996</xref>) and was shown to markedly decrease sensitivity to LSD in one case report (<xref rid="bibr100-02698811231211219" ref-type="bibr">Strassman, 1992</xref>). SSRIs can also result in DDI at the pharmacokinetic level as some of them, such as fluoxetine, are potent inhibitors of CYP2D6 enzymes (<xref rid="bibr16-02698811231211219" ref-type="bibr">Br&#248;sen, 1998</xref>), which can modulate the effects of psychedelics that are being metabolised by such enzymes. For example, CYP2D6 enzymatic activity is already known to influence the effects of LSD (<xref rid="bibr102-02698811231211219" ref-type="bibr">Straumann et al., 2023</xref>; <xref rid="bibr103-02698811231211219" ref-type="bibr">Vizeli et al., 2021</xref>). Considering this, one might have expected a stronger and more prolonged response from LSD instead of reduced effects. However, ultimately this could involve an interplay between various molecular actions, including interactions with enzymes, receptor availability and other molecular factors.</p><p>Trazodone, which was previously described to reduce LSD effects as it is a 5-HT<sub>2A</sub> antagonist, is also a serotonin receptor antagonist and reuptake inhibitor (SARI) (<xref rid="bibr38-02698811231211219" ref-type="bibr">Fagiolini et al., 2012</xref>) that might have a role in the observed effects as well. Potentially, SSRIs and SARIs that increase extracellular serotonin by inhibiting its uptake can then attenuate the effects of psychedelics via receptor competition with the endogenous serotonin. In addition, it has been shown that repeated administration of SSRIs desensitises 5-HT<sub>2A</sub> receptors which may reduce the cell&#8217;s response to psychedelics by binding to these receptors (<xref rid="bibr46-02698811231211219" ref-type="bibr">Gray and Roth, 2001</xref>). Chronic SSRI use can also increase serotonin release via desensitisation of 5-HT<sub>1A</sub> raphe autoreceptors (<xref rid="bibr5-02698811231211219" ref-type="bibr">Artigas et al., 2001</xref>).</p><p>However, one SSRI, escitalopram, did not have an effect on psilocybin-induced positive mood or mind-altering effects (depersonalisation, oceanic boundlessness or euphoria), but it did reduce ego disintegration and anxiety (<xref rid="bibr10-02698811231211219" ref-type="bibr">Becker et al., 2022</xref>). The authors hypothesised that while LSD does not affect the serotonin transporter, psilocin has a weak inhibitory effect on it (<xref rid="bibr10-02698811231211219" ref-type="bibr">Becker et al., 2022</xref>; <xref rid="bibr88-02698811231211219" ref-type="bibr">Rickli et al., 2016</xref>). This distinction in pharmacology could lead to different interactions between antidepressants and LSD compared to psilocybin (<xref rid="bibr10-02698811231211219" ref-type="bibr">Becker et al., 2022</xref>), explaining the differences in response. Although this study offers important insights into the safety of administering psilocybin to patients taking escitalopram, it is crucial to bear in mind that the treatment phase of this study was 14&#8201;days. Longer treatment periods with escitalopram, which may often last for years, could lead to distinct outcomes due to molecular changes that occur over extended periods (<xref rid="bibr39-02698811231211219" ref-type="bibr">Faure et al., 2006</xref>).</p><p>Nonetheless, another study (not included in the results) involved 19 patients with treatment-resistant depression and who were on chronic SSRI treatment (sertraline, escitalopram, fluoxetine, vilazodone, paroxetine or citalopram). The patients were treated with synthetic psilocybin (an investigational drug named &#8216;COMP360&#8217;) and no serious treatment-emergent adverse events were reported (<xref rid="bibr45-02698811231211219" ref-type="bibr">Goodwin et al., 2023</xref>). However, two cases were considered severe (both blood pressure increase) and necessitated treatment with clonidine, but the study did not provide information regarding which specific SSRI treatments these individuals were on. Secondly, although the study measured 5-dimensional altered states of consciousness (5D-ASC) scores, it also did not provide a breakdown by specific SSRIs. This absence of information makes it difficult to assess and compare the individual impacts of different SSRIs on subjective effects as well, particularly given the high standard deviations in the 5D-ASC results and instances of zero scores in three dimensions, indicating some participants did not respond to psilocybin. Improvements in depression severity were observed in 42.1% of cases at week 3, which indicates that ongoing SSRI treatment did not significantly hinder psilocybin&#8217;s therapeutic potential, at least for those participants. Based on the results, the authors hypothesise that chronic SSRI treatment may not significantly downregulate 5-HT<sub>2A/C</sub> receptors, or potentially indicate a lesser impact on the downregulated receptors on the psychedelic experience than previously theorised. It is also possible that unknown mechanisms downstream of 5-HT<sub>2A/C</sub> receptor signalling could compensate for any potential effects of chronic SSRI treatment on the psychedelic response, as they state (<xref rid="bibr45-02698811231211219" ref-type="bibr">Goodwin et al., 2023</xref>). While the study contributes to the body of evidence supporting the safety of using psilocybin alongside SSRI treatment, it is important to note its limitations, including a small sample size and the absence of a breakdown of specific SSRIs. This latter is crucial for linking adverse events and subjective effects to individual drugs, given their distinct properties and potential for varied drug interactions. Due to this, this article was not included in the main results.</p><p>Another study by <xref rid="bibr48-02698811231211219" ref-type="bibr">Gukasyan et al. (2023)</xref>, based on online retrospective survey results, also provided generalised findings for SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs) (thus not included in the primary results). This study reported weakened effects of psilocybin in approximately half of the participants when used concurrently with SSRI/SNRIs, also suggesting downregulation of 5-HT<sub>2A</sub> receptors (<xref rid="bibr48-02698811231211219" ref-type="bibr">Gukasyan et al., 2023</xref>).</p></sec><sec id="section9-02698811231211219"><title>Monoamine oxidase inhibitors</title><p>Results from another antidepressant class, MAOIs, showed a similar outcome to those of SSRIs. In particular, phenelzine, isocarboxazid, nialamide and iproniazid are all non-selective MAO inhibitors (<xref rid="bibr35-02698811231211219" ref-type="bibr">Entzeroth and Ratty, 2017</xref>), therefore inhibiting both MAO-A and MAO-B enzymes. The first three listed antidepressants attenuated or blocked the effects of LSD (<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy, 1996</xref>; <xref rid="bibr47-02698811231211219" ref-type="bibr">Grof and Dytrych, 1965</xref>; <xref rid="bibr85-02698811231211219" ref-type="bibr">Resnick et al., 1964</xref>). By contrast, the latter, iproniazid, did not alter the subjective or physical effects of LSD (<xref rid="bibr27-02698811231211219" ref-type="bibr">DeMaar et al., 1960</xref>). However, iproniazid was also used in the experiments with DMT where it was shown to reduce the effects of DMT (<xref rid="bibr91-02698811231211219" ref-type="bibr">Sai Halasz, 1963</xref>). This particular finding is interesting as iproniazid is an irreversible MAOI (<xref rid="bibr35-02698811231211219" ref-type="bibr">Entzeroth and Ratty, 2017</xref>) that inhibits the enzyme that rapidly metabolises DMT (<xref rid="bibr8-02698811231211219" ref-type="bibr">Barker et al., 1980</xref>). Moreover, studies in rats have shown that iproniazid pretreatment increases levels of DMT in the brain, as well as in the liver, kidney and blood (<xref rid="bibr96-02698811231211219" ref-type="bibr">Sitaram et al., 1987</xref>). However, the reduced DMT effects could be due to increased serotonin levels after blocking MAO and it is hypothesised that higher doses of DMT are needed when serotonin levels are elevated (<xref rid="bibr91-02698811231211219" ref-type="bibr">Sai Halasz, 1963</xref>). It is suggested that ayahuasca&#8217;s effect is mediated by MAO inhibition in the digestive system or bloodstream, which protects DMT from metabolism during its transit to the brain, where MAO inhibitors can then attenuate DMT&#8217;s effects due to elevated brain serotonin (<xref rid="bibr78-02698811231211219" ref-type="bibr">Ott, 1996</xref>). This hypothesis for DMT can also explain the similar, attenuated response, which was observed in the studies where LSD was combined with MAOIs (<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy, 1996</xref>; <xref rid="bibr47-02698811231211219" ref-type="bibr">Grof and Dytrych, 1965</xref>; <xref rid="bibr85-02698811231211219" ref-type="bibr">Resnick et al., 1964</xref>).</p><p>In addition to metabolising DMT, MAOIs are also important in the breakdown of serotonin as they block MAO enzymes involved in its metabolism (<xref rid="bibr40-02698811231211219" ref-type="bibr">Foong et al., 2018</xref>). This gives rise to a possible scenario of excessive serotonin levels in the brain. In particular, when combining MAOIs with each other or with SSRI/SNRI, it has been thought to carry the greatest risk of serotonin toxicity (<xref rid="bibr40-02698811231211219" ref-type="bibr">Foong et al., 2018</xref>). In one case report, symptoms resembling serotonin toxicity were reported after an individual was administered ayahuasca while being on a fluoxetine treatment (<xref rid="bibr19-02698811231211219" ref-type="bibr">Callaway and Grob, 1998</xref>). However, the patient also recovered rapidly within 4&#8201;h after the administration of ayahuasca without any treatment. Moreover, another case report that was not included in the review documented an instance of serotonin toxicity in an individual who had been undergoing <bold>fluoxetine</bold> and <bold>quetiapine</bold> treatment while consuming pure harmal extracted from <italic toggle="yes">Peganum harmala</italic>, which is a component of ayahuasca (<xref rid="bibr6-02698811231211219" ref-type="bibr">Bakim et al., 2012</xref>).</p><p>Ayahuasca brew is usually made from a plant containing DMT and another plant that contains &#946;-carbolines which mostly inhibit MAO-A, thereby making DMT orally active (<xref rid="bibr69-02698811231211219" ref-type="bibr">McKenna, 2004</xref>). Tetrahydroharmine (THH), one of the &#946;-carbolines present in the brew, can also act as a weak serotonin uptake inhibitor and increase brain serotonin levels (<xref rid="bibr3-02698811231211219" ref-type="bibr">Airaksinen et al., 1980</xref>). Fluoxetine strongly inhibits the CYP2D6 enzyme, which metabolises many drugs, including serotonin. The concurrent inhibition of serotonin reuptake and serotonin-metabolising enzymes, such as CYP2D6 and MAO, can cause an accumulation of serotonin in the brain and low clearance, potentially leading to life-threatening serotonin toxicity (<xref rid="bibr32-02698811231211219" ref-type="bibr">Dunkley et al., 2003</xref>). This explanation aligns with the reported case reports; however, further research is necessary to confirm the potential association. While more evidence is required to shed light on the possible DDI, it would be advisable to exercise caution when combining MAOIs found in ayahuasca with SSRIs and SNRIs (e.g. citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine and sertraline).</p><p>There are two case reports in which the consumption of 5-MeO-DMT alongside &#946;-carbolines (MAO-A inhibitors) resulted in a serious adverse event. In one case (<xref rid="bibr17-02698811231211219" ref-type="bibr">Brush et al., 2004</xref>), the ingestion of 5-MeO-DMT in combination with three Syrian rue (<italic toggle="yes">Peganum harmala</italic>) seeds containing harmaline and harmine led to severe agitation, hallucinations, emesis, rhabdomyolysis, diaphoretic skin, hyperthermia and tachycardia. Based on the observed time course and symptoms, the authors suggested the possibility of MAOI poisoning (<xref rid="bibr17-02698811231211219" ref-type="bibr">Brush et al., 2004</xref>). Alternatively, they also considered serotonin toxicity but deemed it less likely. A critical assessment of the report by <xref rid="bibr31-02698811231211219" ref-type="bibr">dos Santos (2013)</xref> suggested serotonin toxicity over MAOI poisoning (<xref rid="bibr31-02698811231211219" ref-type="bibr">dos Santos, 2013</xref>).</p><p>In this case report, it was indicated that three Syrian rue seeds were consumed. However, considering the tiny weight (<xref rid="bibr65-02698811231211219" ref-type="bibr">Li et al., 2023</xref>) and the average content of alkaloids in these seeds (<xref rid="bibr54-02698811231211219" ref-type="bibr">Herraiz et al., 2010</xref>), the estimated total harmaline and harmine content would be only approximately 0.26&#8201;mg and 0.34&#8201;mg, respectively. The combined amount is at least 50 times less than the same alkaloid levels typically used in a standard ayahuasca brew for MAO inhibition (<xref rid="bibr70-02698811231211219" ref-type="bibr">D. J. McKenna et al., 1984</xref>; <xref rid="bibr89-02698811231211219" ref-type="bibr">Rivier and Lindgren, 1972</xref>). While it is challenging to determine the minimum dose of harmaline/harmine necessary for MAO inhibition that induces such adverse effects, it is important to approach this reported consumption of three seeds with a degree of scepticism. It might be possible that the individual may have instead consumed seed capsules, each containing over 50 seeds (<xref rid="bibr71-02698811231211219" ref-type="bibr">Moloudizargari et al., 2013</xref>), totalling approximately over 30&#8201;mg of combined harmaline and harmine for three capsules, comparable to doses used in an ayahuasca brew.</p><p>The second case report (<xref rid="bibr97-02698811231211219" ref-type="bibr">Sklerov et al., 2005</xref>) described the death of a 25-year-old male after he consumed herbal extracts containing &#946;-carbolines and tryptamines. No information is available regarding the composition and dosage of the products but toxicology analysis revealed the presence of 5-MeO-DMT, DMT, MAOIs (harmaline and harmine) and THH (weak serotonin uptake inhibitor). This particular report has faced some criticism for associating toxicity with ayahuasca and for not including several important details (<xref rid="bibr20-02698811231211219" ref-type="bibr">Callaway et al., 2006</xref>). Callaway and his colleagues suggested that the elevated levels of 5-MeO-DMT found in the deceased individual&#8217;s blood likely have a synthetic origin rather than originating from an ayahuasca brew. This conclusion arises because common ingredients in ayahuasca brew do not contain 5-MeO-DMT or, at most, contain only trace amounts of it (<xref rid="bibr20-02698811231211219" ref-type="bibr">Callaway et al., 2006</xref>).</p><p>The toxicity observed in those two case reports remains unclear, but could also have arisen from the impact of MAOIs on the levels of 5-MeO-DMT in the blood and brain as hypothesised by <xref rid="bibr49-02698811231211219" ref-type="bibr">Halberstadt (2016)</xref>. Inhibiting MAO-A activity by &#946;-carbolines could substantially increase concentrations and accumulation of 5-MeO-DMT in the brain and may also lead to interactions with various other targets, potentially giving rise to adverse effects and toxicity (<xref rid="bibr49-02698811231211219" ref-type="bibr">Halberstadt, 2016</xref>; <xref rid="bibr58-02698811231211219" ref-type="bibr">Jiang et al., 2013</xref>). Further evidence is required to confirm the link between 5-MeO-DMT and MAO-A inhibitors. However, based on the case reports, one should exercise caution when combining 5-MeO-DMT with either MAO-A inhibitors (such as harmaline and harmine) or non-selective MAO inhibitors (e.g. medicines such as tranylcypromine, isocarboxazid, phenelzine and selegiline).</p></sec><sec id="section10-02698811231211219"><title>Other drugs (blocking action)</title><p>One study that reported a blocking action on LSD effects was using a high dose of niacin (vitamin B3). Pretreatment with niacin resulted in delayed onset of LSD effects and prevented most of the perceptual changes from occurring, and administration post-LSD ingestion attenuated all effects of LSD within 5&#8201;min (<xref rid="bibr2-02698811231211219" ref-type="bibr">Agnew and Hoffer, 1955</xref>). The blocking mechanism of niacin is not clear but may be due to increased serotonin levels. This is indicated by the studies where niacin has been shown to induce serotonin release from human platelets within a few minutes and to increase plasma serotonin levels in rats (<xref rid="bibr80-02698811231211219" ref-type="bibr">Papaliodis et al., 2008</xref>). Secondly, blocking 5-HT<sub>2A</sub> receptors with ketanserin inhibits niacin-induced temperature increase (<xref rid="bibr80-02698811231211219" ref-type="bibr">Papaliodis et al., 2008</xref>), which indicates that serotonin is involved in the effects of niacin. Finally, high-dose treatment with niacin has caused manic-like psychotic episodes that were thought to occur via stimulation of serotonin but also dopamine production (<xref rid="bibr67-02698811231211219" ref-type="bibr">Loebl and Raskin, 2013</xref>).</p></sec><sec id="section11-02698811231211219"><title>Tricyclic antidepressants</title><p>Several studies have reported the potentiated effects of LSD. In one study, desipramine, imipramine and clomipramine, which are all TCAs, were shown to increase the psychological effects of LSD (<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy, 1996</xref>). Desipramine is a potent inhibitor of noradrenaline reuptake, while imipramine and clomipramine exhibit a lower degree of noradrenaline and serotonin reuptake inhibition (<xref rid="bibr43-02698811231211219" ref-type="bibr">Gillman, 2007</xref>). Furthermore, clomipramine also functions as a 5-HT<sub>2A</sub> receptor antagonist and also imipramine has an affinity for this receptor subtype (<xref rid="bibr43-02698811231211219" ref-type="bibr">Gillman, 2007</xref>).</p><p>Since TCAs were reported to enhance the effects of LSD despite some of them inhibiting serotonin uptake and are even 5-HT<sub>2A</sub> receptor antagonists (similar to SSRIs that decreased the effects of LSD), it is suggested another mechanism can contribute. For instance, chronic administration of TCAs, such as desipramine, can increase the sensitivity of certain neurons to LSD, suggesting that these medications may sensitise postsynaptic serotonin receptors in the brain and therefore be more responsive to LSD (<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy, 1996</xref>). Alternatively, the effects can be enhanced through a dopaminergic system (<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy, 1996</xref>) as chronic use of desipramine has been demonstrated to result in an elevated behavioural response to amphetamine, whereas chronic use of fluoxetine did not have the same effect (<xref rid="bibr98-02698811231211219" ref-type="bibr">Spyraki and Fibiger, 1981</xref>). Therefore, it is possible that the observed effects are due to a modification in the sensitivity of the dopamine receptors. However, it is noteworthy that the results of TCAs originate from a single study with a very small number of participants.</p></sec><sec id="section12-02698811231211219"><title>Other drugs (potentiating action)</title><p>Additionally, from the same study, it was reported that chronic lithium use potentiated LSD effects and resulted in earlier onset (<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy, 1996</xref>). It has been suggested that while acute administration of lithium increases serotonin levels in the brain, chronic administration on the other hand reduces serotonin concentrations (<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy, 1996</xref>). This may explain why long-term lithium use enhances LSD effects, as LSD acts as an agonist in the absence of endogenous serotonin resulting in the observed behavioural effects (<xref rid="bibr13-02698811231211219" ref-type="bibr">Bonson and Murphy, 1996</xref>). It is important to note that these findings and some anecdotal reports that can be found on internet forums suggest a similar outcome, there are also several reported instances of lithium causing seizures when used concurrently with LSD or psilocybin (<xref rid="bibr74-02698811231211219" ref-type="bibr">Nayak et al., 2021</xref>).</p><p>Intensified and prolonged (negative) effects of LSD have also been reported in individuals being pretreated with reserpine, an antihypertensive drug, in three separate studies (<xref rid="bibr41-02698811231211219" ref-type="bibr">Freedman, 1963</xref>; <xref rid="bibr56-02698811231211219" ref-type="bibr">Isbell and Logan, 1957</xref>; <xref rid="bibr86-02698811231211219" ref-type="bibr">Resnick et al., 1965</xref>). Both <xref rid="bibr41-02698811231211219" ref-type="bibr">Freedman (1963)</xref> and <xref rid="bibr56-02698811231211219" ref-type="bibr">Isbell and Logan (1957)</xref> reported tremors that were present after using LSD together with reserpine. Tremors were not observed during LSD use alone (<xref rid="bibr56-02698811231211219" ref-type="bibr">Isbell and Logan, 1957</xref>), and when combined with reserpine, the experience was reported to be less pleasant and lasted longer than LSD use alone (<xref rid="bibr41-02698811231211219" ref-type="bibr">Freedman, 1963</xref>). Furthermore, specific types of hallucinations were reported with reserpine treatment that were not observed during LSD use alone. Overall, individuals reported unpleasant experiences when using an LSD with reserpine.</p><p>Reserpine has the ability to bind to the storage vesicles of certain neurotransmitters, including dopamine and norepinephrine. This binding inhibits the catecholamine pumps and blocks the uptake of serotonin, norepinephrine and dopamine into the presynaptic storage vesicles. Ultimately, this leads to the depletion of these neurotransmitters by cytoplasmic MAO at both central and peripheral synapses (<xref rid="bibr25-02698811231211219" ref-type="bibr">Cheung and Parmar, 2023</xref>). Lower serotonin levels can enhance LSD effects, which was also observed for lithium. However, when LSD was used after chronic administration of lithium, it resulted in positive effects and more vivid hallucinations, without any noted increase in negative psychological or physical side effects as for reserpine. Treatment with reserpine has been known to cause several neurological side effects (<xref rid="bibr25-02698811231211219" ref-type="bibr">Cheung and Parmar, 2023</xref>), and studies have shown that in patients with anxiety it can exacerbate their symptoms (<xref rid="bibr81-02698811231211219" ref-type="bibr">Peterfy et al., 1976</xref>; <xref rid="bibr94-02698811231211219" ref-type="bibr">Sarwer-Foner and Ogle, 1956</xref>). Since LSD can also increase anxiety as a side effect (<xref rid="bibr99-02698811231211219" ref-type="bibr">Strassman, 1984</xref>), it is possible that reserpine treatment could enhance this effect (or <italic toggle="yes">vice versa</italic>), while the modulated hallucinogenic effects of LSD are due to depleted serotonin levels.</p><p>Moreover, reserpine is also a potent inhibitor of both CYP2C19 and CYP2D6 enzymes (<xref rid="bibr34-02698811231211219" ref-type="bibr">Englund et al., 2014</xref>), which are involved in the initial metabolic steps of LSD (<xref rid="bibr106-02698811231211219" ref-type="bibr">Wagmann et al., 2019</xref>). This inhibition may account for the reported prolonged effects of LSD when it was used with reserpine (<xref rid="bibr41-02698811231211219" ref-type="bibr">Freedman, 1963</xref>) as it could potentially decrease the metabolism of LSD. Finally, reserpine acts as an inhibitor of P-glycoprotein as well (<xref rid="bibr34-02698811231211219" ref-type="bibr">Englund et al., 2014</xref>), which can lead to increased concentrations of P-gp substrates. However, no research has been conducted to investigate the impact of P-gp activity on LSD pharmacokinetics and its effects, making it difficult to assess the potential contribution of P-gp inhibition.</p><p>Racemic pindolol, which has an affinity for 5-HT<sub>1A</sub> and &#946;-adrenergic receptors (<xref rid="bibr5-02698811231211219" ref-type="bibr">Artigas et al., 2001</xref>), was reported to intensify the effects of DMT (<xref rid="bibr101-02698811231211219" ref-type="bibr">Strassman, 1996</xref>). The authors suggested a buffering effect of 5-HT<sub>1A</sub> that blocked the 5-HT<sub>2</sub>-mediated psychedelic effects (<xref rid="bibr101-02698811231211219" ref-type="bibr">Strassman, 1996</xref>). However, pindolol has been shown to accelerate, and in some cases, enhance the antidepressant effects of SSRIs. This can be mediated by antagonising 5-HT<sub>1A</sub> autoreceptors in the midbrain raphe and, as a result, preventing the inhibition of serotonin release (<xref rid="bibr5-02698811231211219" ref-type="bibr">Artigas et al., 2001</xref>). DMT is a full agonist at 5-HT<sub>1A</sub> receptors and has a higher affinity for the receptor than it has for 5-HT<sub>2A</sub> receptors where it is a weak partial agonist (<xref rid="bibr61-02698811231211219" ref-type="bibr">Kozell et al., 2023</xref>). Hypothetically, a similar effect as for SSRIs has been described, and can also modulate the effects of DMT, which may have enhanced effects via activating postsynaptic 5-HT<sub>1A</sub> receptors while 5-HT<sub>1A</sub> autoreceptors are blocked.</p><p>A 5-HT<sub>1</sub> receptor agonist and 5-HT<sub>2</sub> receptor antagonist methysergide were similarly shown to potentiate DMT&#8217;s effects (<xref rid="bibr90-02698811231211219" ref-type="bibr">Sai-Halasz, 1962</xref>). This finding adds more weight to the 5-HT<sub>1A</sub> receptor contribution to the effects of DMT, especially considering that methysergide is also an antagonist at the 5-HT<sub>2A</sub> receptors.</p><p>With regards to mescaline use and potentiated effects, one case report involved the use of 2C-O, a structural isomer of mescaline that did not appear to have psychedelic properties on its own (<xref rid="bibr30-02698811231211219" ref-type="bibr">Dittrich, 1971</xref>). However, when used together with mescaline, a synergistic effect may have occurred that potentiated the effects of mescaline described in the case report.</p></sec><sec id="section13-02698811231211219"><title>Other drugs (mixed results)</title><p>Azacyclonol, once investigated as a potential antidepressant, was experimented on individuals who administered LSD and mescaline. Two studies showed no effect of blocking LSD&#8217;s actions (<xref rid="bibr26-02698811231211219" ref-type="bibr">Clark, 1956</xref>; <xref rid="bibr56-02698811231211219" ref-type="bibr">Isbell and Logan, 1957</xref>) and one case report describes the same for mescaline (<xref rid="bibr26-02698811231211219" ref-type="bibr">Clark, 1956</xref>). These results are in contrast to another study that reported the attenuated (pretreatment) or blocked (acute) effects of mescaline after azacyclonol treatment (<xref rid="bibr37-02698811231211219" ref-type="bibr">Fabing, 1955</xref>). The mechanism of action of azacyclonol is not well understood, and the mixed results from the described studies make it difficult to draw firm conclusions and hypotheses.</p></sec><sec id="section14-02698811231211219"><title>Recreational drugs</title><p>Finally, two studies reported the effects of recreational drugs, including MDMA and alcohol consumption on LSD and alcohol on psilocybin. One study, which investigated the effects of alcohol, found that LSD and psilocybin (to a lesser extent) acted as antagonists to the subjective effects of alcohol, while their own psychedelic effects were mainly unaffected (<xref rid="bibr9-02698811231211219" ref-type="bibr">Barrett et al., 2000</xref>). It has been suggested that LSD may block the subjective effects of alcohol by interacting with 5-HT<sub>1B</sub> and 5-HT<sub>1C</sub> receptors, which are implicated in the formation of the ethanol cue (<xref rid="bibr9-02698811231211219" ref-type="bibr">Barrett et al., 2000</xref>). Evidence shows that agonists of these receptors produce responses similar to those of alcohol, whereas blockade of these receptors interferes with the discriminative stimulus properties of alcohol (<xref rid="bibr9-02698811231211219" ref-type="bibr">Barrett et al., 2000</xref>). In the second, a placebo-controlled study (<xref rid="bibr102-02698811231211219" ref-type="bibr">Straumann et al., 2023</xref>), LSD was co-administered with MDMA to investigate the benefits of a combination also known as &#8216;candy-flipping&#8217;. While the particular combination did not yield significant changes as assessed by various instruments, it did result in longer-lasting drug effects (averaging 1.5&#8201;h longer, compared to LSD alone). Also, the combination led to higher plasma concentrations and an extended plasma elimination half-life for LSD, compared to LSD alone. The prolonged drug effects could be attributed to decreased CYP2D6 activity, an enzyme known to be inhibited by MDMA (<xref rid="bibr77-02698811231211219" ref-type="bibr">O&#8217;Math&#250;na et al., 2008</xref>) and involved in LSD metabolism (<xref rid="bibr103-02698811231211219" ref-type="bibr">Vizeli et al., 2021</xref>).</p></sec><sec id="section15-02698811231211219"><title>Limitations</title><p>One of the limitations of this study is the inclusion of a number of old research articles, particularly those published between the 1950s and the 1970s, where many of them provided limited information about the outcomes and/or methods used. Additionally, the limited number of total studies included in this review led to the inclusion of case reports, which may be subject to bias and may provide limited generalisability to larger populations. This review may also have also missed some relevant studies that were published only in non-English languages, which were more common in the early days of research. Finally, this review focused on interactions with LSD, psilocybin, mescaline, 5-MeO-DMT, DMT and ayahuasca, while not including other psychedelics.</p></sec></sec><sec sec-type="conclusions" id="section16-02698811231211219"><title>Conclusions</title><p>In this systematic review, we observed DDIs at both pharmacodynamic and (likely) pharmacokinetic levels that may block or decrease the response to psychedelics, or alternatively potentiate and lengthen the duration of psychological and/or physical effects. While there is strong evidence of 5-HT<sub>2A</sub> receptor involvement in the effects of psychedelics, some research included in this review suggests that other serotonin receptors, such as 5-HT<sub>1A/B</sub> and dopamine receptors, along with altered serotonin levels, may also modulate psychological and/or physical effects. Additionally, a small number of studies reviewed indicated a potential role of the 5-HT<sub>1</sub> receptor subtype in modulating the effects of DMT. It appears that although different psychedelics may yield similar subjective effects, their pharmacological properties differ, resulting in potentially varying interaction effects when combined with other drugs. Overall, given the limited number of papers exploring DDIs associated with psychedelics and the resurgence of scientific and medical interest in these compounds, further research is needed to improve understanding of such interactions, and identify novel drug interactions and potentially serious adverse reactions not currently described in the literature.</p></sec><sec sec-type="supplementary-material" id="section17-02698811231211219" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="suppl1-02698811231211219" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-1-jop-10.1177_02698811231211219 &#8211; Supplemental material for Drug&#8211;drug interactions involving classic psychedelics: A systematic review</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-1-jop-10.1177_02698811231211219.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, sj-docx-1-jop-10.1177_02698811231211219 for Drug&#8211;drug interactions involving classic psychedelics: A systematic review by Andreas Halman, Geraldine Kong, Jerome Sarris and Daniel Perkins in Journal of Psychopharmacology</p></supplementary-material></sec></body><back><ack><p>The authors acknowledge Eleanor White for her contribution to an earlier version of the introduction.</p></ack><fn-group><fn fn-type="COI-statement"><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JS and DP are directors of a not-for-profit research institute which has in the past received commercial funding to undertake psychedelic medicines research.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Andreas Halman <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_02698811231211219-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-5248-4121" ext-link-type="uri">https://orcid.org/0000-0001-5248-4121</ext-link></p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abramson</surname><given-names>HA</given-names></name><name name-style="western"><surname>Rolo</surname><given-names>A</given-names></name><name name-style="western"><surname>Stache</surname><given-names>J</given-names></name></person-group> (<year>1960</year>) <article-title>Lysergic acid diethylamide (LSD-25) antagonists- chlorpromazine.pdf</article-title>. <source>J Neuropsychiatry</source><volume>1</volume>: <fpage>307</fpage>&#8211;<lpage>310</lpage>.<pub-id pub-id-type="pmid">13791577</pub-id></mixed-citation></ref><ref id="bibr2-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnew</surname><given-names>N</given-names></name><name name-style="western"><surname>Hoffer</surname><given-names>A</given-names></name></person-group> (<year>1955</year>) <article-title>Nicotinic acid modified lysergic acid diethylamide psychosis</article-title>. <source>J Ment Sci</source><volume>101</volume>: <fpage>12</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">14368207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.101.422.12</pub-id></mixed-citation></ref><ref id="bibr3-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Airaksinen</surname><given-names>MM</given-names></name><name name-style="western"><surname>Svensk</surname><given-names>H</given-names></name><name name-style="western"><surname>Tuomisto</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal> (<year>1980</year>) <article-title>Tetrahydro-beta-carbolines and corresponding tryptamines: In vitro inhibition of serotonin and dopamine uptake by human blood platelets</article-title>. <source>Acta Pharmacol Toxicol</source><volume>46</volume>: <fpage>308</fpage>&#8211;<lpage>313</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0773.1980.tb02459.x</pub-id><pub-id pub-id-type="pmid">7368950</pub-id></mixed-citation></ref><ref id="bibr4-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amin</surname><given-names>ML</given-names></name></person-group> (<year>2013</year>) <article-title>P-glycoprotein inhibition for optimal drug delivery</article-title>. <source>Drug Target Insights</source><volume>7</volume>: <fpage>27</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">24023511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4137/DTI.S12519</pub-id><pub-id pub-id-type="pmcid">PMC3762612</pub-id></mixed-citation></ref><ref id="bibr5-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Artigas</surname><given-names>F</given-names></name><name name-style="western"><surname>Celada</surname><given-names>P</given-names></name><name name-style="western"><surname>Laruelle</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal> (<year>2001</year>) <article-title>How does pindolol improve antidepressant action?</article-title><source>Trends Pharmacol Sci</source><volume>22</volume>: <fpage>224</fpage>&#8211;<lpage>228</lpage>.<pub-id pub-id-type="pmid">11339972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0165-6147(00)01682-5</pub-id></mixed-citation></ref><ref id="bibr6-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakim</surname><given-names>B</given-names></name><name name-style="western"><surname>Sertcelik</surname><given-names>S</given-names></name><name name-style="western"><surname>Tankaya</surname><given-names>O</given-names></name></person-group> (<year>2012</year>) <article-title>A case of serotonin syndrome with antidepressant treatment and concomitant use of the herbal remedy (Peganum Harmala)</article-title>. <source>Klinik Psikofarmakoloji B&#252;lteni-Bull Clin Psychopharmacol</source><volume>22</volume>: <fpage>359</fpage>&#8211;<lpage>361</lpage>.</mixed-citation></ref><ref id="bibr7-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balsara</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Jadhav</surname><given-names>SA</given-names></name><name name-style="western"><surname>Gaonkar</surname><given-names>RK</given-names></name></person-group>, <etal>et al</etal> (<year>2005</year>). <article-title>Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats</article-title>. <source>Psychopharmacology</source><volume>179</volume>: <fpage>597</fpage>&#8211;<lpage>605</lpage>.<pub-id pub-id-type="pmid">15614572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-004-2095-0</pub-id></mixed-citation></ref><ref id="bibr8-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barker</surname><given-names>SA</given-names></name><name name-style="western"><surname>Monti</surname><given-names>JA</given-names></name><name name-style="western"><surname>Christian</surname><given-names>ST</given-names></name></person-group> (<year>1980</year>) <article-title>Metabolism of the hallucinogen N,N-dimethyltryptamine in rat brain homogenates</article-title>. <source>BiochemPharmacol</source><volume>29</volume>: <fpage>1049</fpage>&#8211;<lpage>1057</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(80)90169-0</pub-id><pub-id pub-id-type="pmid">6770869</pub-id></mixed-citation></ref><ref id="bibr9-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>SP</given-names></name><name name-style="western"><surname>Archambault</surname><given-names>J</given-names></name><name name-style="western"><surname>Engelberg</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal> (<year>2000</year>) <article-title>Hallucinogenic drugs attenuate the subjective response to alcohol in humans</article-title>. <source>Hum Psychopharmacol</source><volume>15</volume>: <fpage>559</fpage>&#8211;<lpage>565</lpage>.<pub-id pub-id-type="pmid">12404626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1099-1077(200010)15:7&lt;559::AID-HUP230&gt;3.0.CO;2-J</pub-id></mixed-citation></ref><ref id="bibr10-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>AM</given-names></name><name name-style="western"><surname>Holze</surname><given-names>F</given-names></name><name name-style="western"><surname>Grandinetti</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal> (<year>2022</year>) <article-title>Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects</article-title>. <source>Clin Pharmacol Therap</source><volume>111</volume>: <fpage>886</fpage>&#8211;<lpage>895</lpage>.<pub-id pub-id-type="pmid">34743319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2487</pub-id><pub-id pub-id-type="pmcid">PMC9299061</pub-id></mixed-citation></ref><ref id="bibr11-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>AM</given-names></name><name name-style="western"><surname>Klaiber</surname><given-names>A</given-names></name><name name-style="western"><surname>Holze</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal> (<year>2023</year>) <article-title>Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants</article-title>. <source>Int J Neuropsychopharmacol/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum</source><volume>26</volume>: <fpage>97</fpage>&#8211;<lpage>106</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ijnp/pyac075</pub-id><pub-id pub-id-type="pmcid">PMC9926053</pub-id><pub-id pub-id-type="pmid">36342343</pub-id></mixed-citation></ref><ref id="bibr12-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonson</surname><given-names>KR</given-names></name><name name-style="western"><surname>Buckholtz</surname><given-names>JW</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>DL</given-names></name></person-group> (<year>1996</year>) <article-title>Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans</article-title>. <source>Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol</source><volume>14</volume>: <fpage>425</fpage>&#8211;<lpage>436</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0893-133X(95)00145-4</pub-id><pub-id pub-id-type="pmid">8726753</pub-id></mixed-citation></ref><ref id="bibr13-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonson</surname><given-names>KR</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>DL</given-names></name></person-group> (<year>1996</year>) <article-title>Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium</article-title>. <source>Behav Brain Res</source><volume>73</volume>: <fpage>229</fpage>&#8211;<lpage>233</lpage>.<pub-id pub-id-type="pmid">8788508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0166-4328(96)00102-7</pub-id></mixed-citation></ref><ref id="bibr14-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyd-Kimball</surname><given-names>D</given-names></name><name name-style="western"><surname>Gonczy</surname><given-names>K</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal> (<year>2019</year>) <article-title>Classics in chemical neuroscience: Chlorpromazine</article-title>. <source>ACS Chem Neurosci</source><volume>10</volume>: <fpage>79</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">29929365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.8b00258</pub-id></mixed-citation></ref><ref id="bibr15-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito-da-Costa</surname><given-names>AM</given-names></name><name name-style="western"><surname>Dias-da-Silva</surname><given-names>D</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>NGM</given-names></name></person-group>, <etal>et al</etal> (<year>2020</year>) <article-title>Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: Clinical and forensic impact</article-title>. <source>Pharmaceuticals</source><volume>13</volume>: <fpage>334</fpage>. DOI: <pub-id pub-id-type="doi">10.3390/ph13110334.</pub-id><pub-id pub-id-type="pmid">33114119</pub-id><pub-id pub-id-type="pmcid">PMC7690791</pub-id></mixed-citation></ref><ref id="bibr16-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#248;sen</surname><given-names>K</given-names></name></person-group> (<year>1998</year>) <article-title>Differences in interactions of SSRIs</article-title>. <source>Int Clin Psychopharmacol</source><volume>13</volume>: S45&#8211;S47.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00004850-199809005-00009</pub-id><pub-id pub-id-type="pmid">9817620</pub-id></mixed-citation></ref><ref id="bibr17-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brush</surname><given-names>DE</given-names></name><name name-style="western"><surname>Bird</surname><given-names>SB</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>EW</given-names></name></person-group> (<year>2004</year>) <article-title>Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances</article-title>. <source>J Toxicol, Clin Toxicol</source><volume>42</volume>: <fpage>191</fpage>&#8211;<lpage>195</lpage>.<pub-id pub-id-type="pmid">15214625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1081/clt-120030949</pub-id></mixed-citation></ref><ref id="bibr18-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cakic</surname><given-names>V</given-names></name><name name-style="western"><surname>Potkonyak</surname><given-names>J</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>A</given-names></name></person-group> (<year>2010</year>) <article-title>Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users</article-title>. <source>Drug Alcohol Depend</source><volume>111</volume>: <fpage>30</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">20570058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2010.03.015</pub-id></mixed-citation></ref><ref id="bibr19-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>JC</given-names></name><name name-style="western"><surname>Grob</surname><given-names>CS</given-names></name></person-group> (<year>1998</year>) <article-title>Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions</article-title>. <source>J Psychoact Drugs</source><volume>30</volume>: <fpage>367</fpage>&#8211;<lpage>369</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02791072.1998.10399712</pub-id><pub-id pub-id-type="pmid">9924842</pub-id></mixed-citation></ref><ref id="bibr20-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>JC</given-names></name><name name-style="western"><surname>Grob</surname><given-names>CS</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>DJ</given-names></name></person-group>, <etal>et al</etal> (<year>2006</year>). <article-title>A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation [Review of A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation]</article-title>. <source>J Anal Toxicol</source><volume>30</volume>: <fpage>406</fpage>&#8211;<lpage>407</lpage>.<pub-id pub-id-type="pmid">16872575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jat/30.6.406</pub-id></mixed-citation></ref><ref id="bibr21-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calvey</surname><given-names>T</given-names></name><name name-style="western"><surname>Howells</surname><given-names>FM</given-names></name></person-group> (<year>2018</year>) <article-title>Chapter 1 - An introduction to psychedelic neuroscience</article-title>. <source>Prog Brain Res</source><volume>242</volume>: <fpage>1</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">30471677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pbr.2018.09.013</pub-id></mixed-citation></ref><ref id="bibr22-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carbonaro</surname><given-names>TM</given-names></name><name name-style="western"><surname>Gatch</surname><given-names>MB</given-names></name></person-group> (<year>2016</year>) <article-title>Neuropharmacology of N,N-dimethyltryptamine</article-title>. <source>Brain Res Bull</source><volume>126</volume>: <fpage>74</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">27126737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2016.04.016</pub-id><pub-id pub-id-type="pmcid">PMC5048497</pub-id></mixed-citation></ref><ref id="bibr23-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>OL</given-names></name><name name-style="western"><surname>Burr</surname><given-names>DC</given-names></name><name name-style="western"><surname>Pettigrew</surname><given-names>JD</given-names></name></person-group>, <etal>et al</etal> (<year>2005</year>) <article-title>Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors</article-title>. <source>J Cogn Neurosci</source><volume>17</volume>: <fpage>1497</fpage>&#8211;<lpage>1508</lpage>.<pub-id pub-id-type="pmid">16269092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1162/089892905774597191</pub-id></mixed-citation></ref><ref id="bibr24-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>OL</given-names></name><name name-style="western"><surname>Hasler</surname><given-names>F</given-names></name><name name-style="western"><surname>Pettigrew</surname><given-names>JD</given-names></name></person-group>, <etal>et al</etal> (<year>2007</year>) <article-title>Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans</article-title>. <source>Psychopharmacology</source><volume>195</volume>: <fpage>415</fpage>&#8211;<lpage>424</lpage>.<pub-id pub-id-type="pmid">17874073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-007-0930-9</pub-id></mixed-citation></ref><ref id="bibr25-02698811231211219"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>M</given-names></name><name name-style="western"><surname>Parmar</surname><given-names>M</given-names></name></person-group> (<year>2023</year>) <source>Reserpine</source>. <publisher-name>StatPearls Publishing</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK557767/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK557767/</ext-link><pub-id pub-id-type="pmid">32491699</pub-id></mixed-citation></ref><ref id="bibr26-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>LD</given-names></name></person-group> (<year>1956</year>) <article-title>Further studies of the psychological effects of frenquel and a critical review of previous reports</article-title>. <source>J Nerv Ment Dis</source><volume>123</volume>: <fpage>557</fpage>&#8211;<lpage>560</lpage>.<pub-id pub-id-type="pmid">13406582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005053-195606000-00008</pub-id></mixed-citation></ref><ref id="bibr27-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMaar</surname><given-names>EWJ</given-names></name><name name-style="western"><surname>Williams</surname><given-names>HL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>AI</given-names></name></person-group>, <etal>et al</etal> (<year>1960</year>) <article-title>Effects in man of single and combined oral doses of reserpine, iproniazid, and D-lysergic acid diethylamide</article-title>. <source>Clin Pharmacol Therap</source><volume>1</volume>: <fpage>23</fpage>&#8211;<lpage>30</lpage>.</mixed-citation></ref><ref id="bibr28-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinis-Oliveira</surname><given-names>RJ</given-names></name></person-group> (<year>2017</year>) <article-title>Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance</article-title>. <source>Drug Metab Rev</source><volume>49</volume>: <fpage>84</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">28074670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03602532.2016.1278228</pub-id></mixed-citation></ref><ref id="bibr29-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinis-Oliveira</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>CL</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>DD</given-names></name></person-group> (<year>2019</year>) <article-title>Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: Clinical and forensic repercussions</article-title>. <source>Curr Mol Pharmacol</source><volume>12</volume>: <fpage>184</fpage>&#8211;<lpage>194</lpage>.<pub-id pub-id-type="pmid">30318013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1874467211666181010154139</pub-id><pub-id pub-id-type="pmcid">PMC6864602</pub-id></mixed-citation></ref><ref id="bibr30-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dittrich</surname><given-names>A</given-names></name></person-group> (<year>1971</year>) <article-title>Alteration of behavioural changes induced by 3,4,5-trimethoxyphenylethylamine (mescaline) by pretreatment with 2,4,5-trimethoxyphenylethylamine</article-title>. <source>Psychopharmacologia</source><volume>21</volume>: <fpage>229</fpage>&#8211;<lpage>237</lpage>.<pub-id pub-id-type="pmid">5095413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00403861</pub-id></mixed-citation></ref><ref id="bibr31-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>dos Santos</surname><given-names>RG</given-names></name></person-group> (<year>2013</year>) <article-title>A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions</article-title>. <source>J Psychoact Drugs</source><volume>45</volume>: <fpage>179</fpage>&#8211;<lpage>188</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02791072.2013.785846</pub-id><pub-id pub-id-type="pmid">23909005</pub-id></mixed-citation></ref><ref id="bibr32-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunkley</surname><given-names>EJC</given-names></name><name name-style="western"><surname>Isbister</surname><given-names>GK</given-names></name><name name-style="western"><surname>Sibbritt</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal> (<year>2003</year>) <article-title>The hunter serotonin toxicity criteria: Simple and accurate diagnostic decision rules for serotonin toxicity</article-title>. <source>QJM: Mon J Assoc Physicians</source><volume>96</volume>: <fpage>635</fpage>&#8211;<lpage>642</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/qjmed/hcg109</pub-id><pub-id pub-id-type="pmid">12925718</pub-id></mixed-citation></ref><ref id="bibr33-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egan</surname><given-names>C</given-names></name><name name-style="western"><surname>Grinde</surname><given-names>E</given-names></name><name name-style="western"><surname>Dupre</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal> (<year>2000</year>). <article-title>Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors</article-title>. <source>Synapse</source><volume>35</volume>: <fpage>144</fpage>&#8211;<lpage>150</lpage>.<pub-id pub-id-type="pmid">10611640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1098-2396(200002)35:2&lt;144::AID-SYN7&gt;3.0.CO;2-K</pub-id></mixed-citation></ref><ref id="bibr34-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Englund</surname><given-names>G</given-names></name><name name-style="western"><surname>Lundquist</surname><given-names>P</given-names></name><name name-style="western"><surname>Skogastierna</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal> (<year>2014</year>). <article-title>Cytochrome p450 inhibitory properties of common efflux transporter inhibitors</article-title>. <source>Drug Metab Dispos: Biol Fate Chem</source><volume>42</volume>(<issue>3</issue>): <fpage>441</fpage>&#8211;<lpage>447</lpage>.<pub-id pub-id-type="pmid">24396142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.113.054932</pub-id></mixed-citation></ref><ref id="bibr35-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Entzeroth</surname><given-names>M</given-names></name><name name-style="western"><surname>Ratty</surname><given-names>AK</given-names></name></person-group> (<year>2017</year>) <article-title>Monoamine oxidase inhibitors&#8212;revisiting a therapeutic principle</article-title>. <source>Open J Depress</source><volume>6</volume>: <fpage>31</fpage>&#8211;<lpage>68</lpage>.</mixed-citation></ref><ref id="bibr36-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ermakova</surname><given-names>AO</given-names></name><name name-style="western"><surname>Dunbar</surname><given-names>F</given-names></name><name name-style="western"><surname>Rucker</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal> (<year>2022</year>) <article-title>A narrative synthesis of research with 5-MeO-DMT</article-title>. <source>J Psychopharmacol</source><volume>36</volume>: <fpage>273</fpage>&#8211;<lpage>294</lpage>.<pub-id pub-id-type="pmid">34666554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/02698811211050543</pub-id><pub-id pub-id-type="pmcid">PMC8902691</pub-id></mixed-citation></ref><ref id="bibr37-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabing</surname><given-names>HD</given-names></name></person-group> (<year>1955</year>) <article-title>Frenquel, a blocking agent against experimental LSD-25 and mescaline psychosis; preliminary note on its clinical application</article-title>. <source>Neurology</source><volume>5</volume>: <fpage>319</fpage>&#8211;<lpage>328</lpage>.<pub-id pub-id-type="pmid">14370384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.5.5.319</pub-id></mixed-citation></ref><ref id="bibr38-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fagiolini</surname><given-names>A</given-names></name><name name-style="western"><surname>Comandini</surname><given-names>A</given-names></name><name name-style="western"><surname>Catena Dell&#8217;Osso</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal> (<year>2012</year>). <article-title>Rediscovering trazodone for the treatment of major depressive disorder</article-title>. <source>CNS Drugs</source><volume>26</volume>: <fpage>1033</fpage>&#8211;<lpage>1049</lpage>.<pub-id pub-id-type="pmid">23192413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40263-012-0010-5</pub-id><pub-id pub-id-type="pmcid">PMC3693429</pub-id></mixed-citation></ref><ref id="bibr39-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faure</surname><given-names>C</given-names></name><name name-style="western"><surname>Mnie-Filali</surname><given-names>O</given-names></name><name name-style="western"><surname>Haddjeri</surname><given-names>N</given-names></name></person-group> (<year>2006</year>) <article-title>Long-term adaptive changes induced by serotonergic antidepressant drugs</article-title>. <source>Exp Rev Neurother</source><volume>6</volume>: <fpage>235</fpage>&#8211;<lpage>245</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14737175.6.2.235</pub-id><pub-id pub-id-type="pmid">16466303</pub-id></mixed-citation></ref><ref id="bibr40-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foong</surname><given-names>A-L</given-names></name><name name-style="western"><surname>Grindrod</surname><given-names>KA</given-names></name><name name-style="western"><surname>Patel</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal> (<year>2018</year>) <article-title>Demystifying serotonin syndrome (or serotonin toxicity)</article-title>. <source>Can Fam Phys Med Fam Can</source><volume>64</volume>: <fpage>720</fpage>&#8211;<lpage>727</lpage>.<pub-id pub-id-type="pmcid">PMC6184959</pub-id><pub-id pub-id-type="pmid">30315014</pub-id></mixed-citation></ref><ref id="bibr41-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedman</surname><given-names>DX</given-names></name></person-group> (<year>1963</year>) <article-title>Psychotomimetic drugs and brain biogenic amines</article-title>. <source>Am J Psychiatry</source><volume>119</volume>: <fpage>843</fpage>&#8211;<lpage>850</lpage>.<pub-id pub-id-type="pmid">13959421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/ajp.119.9.843</pub-id></mixed-citation></ref><ref id="bibr42-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillman</surname><given-names>PK</given-names></name></person-group> (<year>1999</year>) <article-title>The serotonin syndrome and its treatment</article-title>. <source>J Psychopharmacol</source><volume>13</volume>: <fpage>100</fpage>&#8211;<lpage>109</lpage>.<pub-id pub-id-type="pmid">10221364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/026988119901300111</pub-id></mixed-citation></ref><ref id="bibr43-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillman</surname><given-names>PK</given-names></name></person-group> (<year>2007</year>) <article-title>Tricyclic antidepressant pharmacology and therapeutic drug interactions updated</article-title>. <source>Br J Pharmacol</source><volume>151</volume>: <fpage>737</fpage>&#8211;<lpage>748</lpage>.<pub-id pub-id-type="pmid">17471183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjp.0707253</pub-id><pub-id pub-id-type="pmcid">PMC2014120</pub-id></mixed-citation></ref><ref id="bibr44-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Good</surname><given-names>M</given-names></name><name name-style="western"><surname>Benway</surname><given-names>T</given-names></name><name name-style="western"><surname>Joel</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal> (<year>2022</year>) <article-title>Pharmacokinetics Of N,N-dimethyltryptamine fumarate in humans</article-title>. <source>Authorea Preprints</source>. DOI: <pub-id pub-id-type="doi">10.22541/au.165237523.39763980/v1.</pub-id></mixed-citation></ref><ref id="bibr45-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>GM</given-names></name><name name-style="western"><surname>Croal</surname><given-names>M</given-names></name><name name-style="western"><surname>Feifel</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal> (<year>2023</year>) <article-title>Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication</article-title>. <source>Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol</source><volume>48</volume>: <fpage>1492</fpage>&#8211;<lpage>1499</lpage>. DOI: <pub-id pub-id-type="doi">10.1038/s41386-023-01648-7.</pub-id><pub-id pub-id-type="pmcid">PMC10425429</pub-id><pub-id pub-id-type="pmid">37443386</pub-id></mixed-citation></ref><ref id="bibr46-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>JA</given-names></name><name name-style="western"><surname>Roth</surname><given-names>BL</given-names></name></person-group> (<year>2001</year>) <article-title>Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists</article-title>. <source>Brain Res Bull</source><volume>56</volume>: <fpage>441</fpage>&#8211;<lpage>451</lpage>.<pub-id pub-id-type="pmid">11750789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0361-9230(01)00623-2</pub-id></mixed-citation></ref><ref id="bibr47-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grof</surname><given-names>S</given-names></name><name name-style="western"><surname>Dytrych</surname><given-names>Z</given-names></name></person-group> (<year>1965</year>) <article-title>Blocking of LSD reaction by premedication with Niamid</article-title>. <source>Act Nerv Super</source><volume>7</volume>: <fpage>306</fpage>.<pub-id pub-id-type="pmid">5882136</pub-id></mixed-citation></ref><ref id="bibr48-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gukasyan</surname><given-names>N</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>RR</given-names></name><name name-style="western"><surname>Yaden</surname><given-names>DB</given-names></name></person-group>, <etal>et al</etal> (<year>2023</year>) <article-title>Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use</article-title>. <source>J Psychopharmacol</source><volume>37</volume>: <fpage>707</fpage>&#8211;<lpage>716</lpage>.<pub-id pub-id-type="pmid">37291890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/02698811231179910</pub-id></mixed-citation></ref><ref id="bibr49-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halberstadt</surname><given-names>AL</given-names></name></person-group> (<year>2016</year>) <article-title>Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine</article-title>. <source>Pharmacol Biochem Behav</source><volume>143</volume>: <fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">26780349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pbb.2016.01.005</pub-id><pub-id pub-id-type="pmcid">PMC5403252</pub-id></mixed-citation></ref><ref id="bibr50-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halberstadt</surname><given-names>AL</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>MA</given-names></name></person-group> (<year>2011</year>) <article-title>Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens</article-title>. <source>Neuropharmacology</source><volume>61</volume>(<issue>3</issue>): <fpage>364</fpage>&#8211;<lpage>381</lpage>.<pub-id pub-id-type="pmid">21256140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2011.01.017</pub-id><pub-id pub-id-type="pmcid">PMC3110631</pub-id></mixed-citation></ref><ref id="bibr51-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halberstadt</surname><given-names>AL</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>DE</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>MA</given-names></name></person-group> (<year>2012</year>) <article-title>Behavioral effects of &#945;,&#945;,&#946;,&#946;-tetradeutero-5-MeO-DMT in rats: Comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor</article-title>. <source>Psychopharmacology</source><volume>221</volume>(<issue>4</issue>): <fpage>709</fpage>&#8211;<lpage>718</lpage>.<pub-id pub-id-type="pmid">22222861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-011-2616-6</pub-id><pub-id pub-id-type="pmcid">PMC3796951</pub-id></mixed-citation></ref><ref id="bibr52-02698811231211219"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Halman</surname><given-names>A</given-names></name><name name-style="western"><surname>Oshlack</surname><given-names>A</given-names></name></person-group> (<year>2023</year>) <article-title>Catchii: Empowering literature review screening in healthcare</article-title>. <source>Res Syn Meth</source><fpage>1</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/jrsm.1675</pub-id><pub-id pub-id-type="pmid">37771210</pub-id></mixed-citation></ref><ref id="bibr53-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemeryck</surname><given-names>A</given-names></name><name name-style="western"><surname>Belpaire</surname><given-names>FM</given-names></name></person-group> (<year>2002</year>) <article-title>Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update</article-title>. <source>Curr Drug Metab</source><volume>3</volume>: <fpage>13</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">11876575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389200023338017</pub-id></mixed-citation></ref><ref id="bibr54-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herraiz</surname><given-names>T</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>D</given-names></name><name name-style="western"><surname>Anc&#237;n-Azpilicueta</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal> (<year>2010</year>) <article-title>Beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)</article-title>. <source>Food Chem Toxicol: Int J Publ Br Ind Biol Res Assoc</source><volume>48</volume>: <fpage>839</fpage>&#8211;<lpage>845</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fct.2009.12.019</pub-id><pub-id pub-id-type="pmid">20036304</pub-id></mixed-citation></ref><ref id="bibr55-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holze</surname><given-names>F</given-names></name><name name-style="western"><surname>Vizeli</surname><given-names>P</given-names></name><name name-style="western"><surname>Ley</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal> (<year>2021</year>) <article-title>Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects</article-title>. <source>Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol</source><volume>46</volume>: <fpage>537</fpage>&#8211;<lpage>544</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-020-00883-6</pub-id><pub-id pub-id-type="pmcid">PMC8027607</pub-id><pub-id pub-id-type="pmid">33059356</pub-id></mixed-citation></ref><ref id="bibr56-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isbell</surname><given-names>H</given-names></name><name name-style="western"><surname>Logan</surname><given-names>CR</given-names></name></person-group> (<year>1957</year>) <article-title>Studies on the diethylamide of lysergic acid (LSD-25). II. Effects of chlorpromazine, azacyclonol, and reserpine on the intensity of the LSD-reaction</article-title>. <source>A.M.A. Arch Neurol Psychiatry</source><volume>77</volume>: <fpage>350</fpage>&#8211;<lpage>358</lpage>.<pub-id pub-id-type="pmid">13410191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurpsyc.1957.02330340026002</pub-id></mixed-citation></ref><ref id="bibr57-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isbell</surname><given-names>H</given-names></name><name name-style="western"><surname>Logan</surname><given-names>CR</given-names></name><name name-style="western"><surname>Miner</surname><given-names>EJ</given-names></name></person-group> (<year>1959</year>) <article-title>Studies on lysergic acid diethylamide (LSD-25). III. Attempts to attenuate the LSD-reaction in man by pretreatment with neurohumoral blocking agents</article-title>. <source>A.M.A. Arch Neurol Psychiatry</source><volume>81</volume>: <fpage>20</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">13605318</pub-id></mixed-citation></ref><ref id="bibr58-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X-L</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H-W</given-names></name><name name-style="western"><surname>Mager</surname><given-names>DE</given-names></name></person-group>, <etal>et al</etal> (<year>2013</year>) <article-title>Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status</article-title>. <source>Drug Metab Dispos: Biol Fate Chem</source><volume>41</volume>: <fpage>975</fpage>&#8211;<lpage>986</lpage>.<pub-id pub-id-type="pmid">23393220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.112.050724</pub-id><pub-id pub-id-type="pmcid">PMC3629804</pub-id></mixed-citation></ref><ref id="bibr59-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jim&#233;nez</surname><given-names>JH</given-names></name><name name-style="western"><surname>Bouso</surname><given-names>JC</given-names></name></person-group> (<year>2022</year>) <article-title>Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate</article-title>. <source>J Psychopharmacol</source><volume>36</volume>: <fpage>905</fpage>&#8211;<lpage>919</lpage>.<pub-id pub-id-type="pmid">35695604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/02698811221104054</pub-id></mixed-citation></ref><ref id="bibr60-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keeler</surname><given-names>MH</given-names></name></person-group> (<year>1967</year>) <article-title>Chlorpromazine antagonism of psilocybin effect</article-title>. <source>International Journal of Neuropsychiatry</source><volume>3</volume>: <fpage>66</fpage>&#8211;<lpage>71</lpage>.</mixed-citation></ref><ref id="bibr61-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozell</surname><given-names>LB</given-names></name><name name-style="western"><surname>Eshleman</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>TL</given-names></name></person-group>, <etal>et al</etal> (<year>2023</year>) <article-title>Pharmacologic activity of substituted tryptamines at 5-hydroxytryptamine (5-HT)2A receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and serotonin transporter</article-title>. <source>J Pharmacol Exp Therap</source><volume>385</volume>: <fpage>62</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">36669875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.122.001454</pub-id><pub-id pub-id-type="pmcid">PMC10029822</pub-id></mixed-citation></ref><ref id="bibr62-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>DG</given-names></name></person-group> (<year>2004</year>) <article-title>Drugs and receptors</article-title>. <source>Cont Edu Anaesth Crit Care Pain</source><volume>4</volume>: <fpage>181</fpage>&#8211;<lpage>184</lpage>.</mixed-citation></ref><ref id="bibr63-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawn</surname><given-names>T</given-names></name><name name-style="western"><surname>Dipasquale</surname><given-names>O</given-names></name><name name-style="western"><surname>Vamvakas</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal> (<year>2022</year>) <article-title>Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD</article-title>. <source>Psychopharmacology</source><volume>239</volume>: <fpage>1797</fpage>&#8211;<lpage>1808</lpage>.<pub-id pub-id-type="pmid">35322297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-022-06117-5</pub-id><pub-id pub-id-type="pmcid">PMC9166846</pub-id></mixed-citation></ref><ref id="bibr64-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lesse</surname><given-names>S</given-names></name></person-group> (<year>1958</year>) <article-title>Psychodynamic relationships between the degree of anxiety and other clinical symptoms</article-title>. <source>J Nerv Ment Dis</source><volume>127</volume>: <fpage>124</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">13576128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005053-195808000-00004</pub-id></mixed-citation></ref><ref id="bibr65-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Yan</surname><given-names>N</given-names></name><name name-style="western"><surname>Tanveer</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal> (<year>2023</year>) <article-title>Seed germination ecology of the medicinal plant peganum harmala (Zygophyllaceae)</article-title>. <source>Plants</source><volume>12</volume>: <fpage>2660</fpage>. DOI: <pub-id pub-id-type="doi">10.3390/plants12142660.</pub-id><pub-id pub-id-type="pmid">37514274</pub-id><pub-id pub-id-type="pmcid">PMC10384465</pub-id></mixed-citation></ref><ref id="bibr66-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loane</surname><given-names>C</given-names></name><name name-style="western"><surname>Politis</surname><given-names>M</given-names></name></person-group> (<year>2012</year>) <article-title>Buspirone: What is it all about?</article-title><source>Brain Res</source><volume>1461</volume>: <fpage>111</fpage>&#8211;<lpage>118</lpage>.<pub-id pub-id-type="pmid">22608068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2012.04.032</pub-id></mixed-citation></ref><ref id="bibr67-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loebl</surname><given-names>T</given-names></name><name name-style="western"><surname>Raskin</surname><given-names>S</given-names></name></person-group> (<year>2013</year>) <article-title>A novel case report: Acute manic psychotic episode after treatment with niacin</article-title>. <source>J Neuropsychiatry Clin Neurosci</source><volume>25</volume>: E14.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.neuropsych.12090212</pub-id><pub-id pub-id-type="pmid">24247871</pub-id></mixed-citation></ref><ref id="bibr68-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luethi</surname><given-names>D</given-names></name><name name-style="western"><surname>Hoener</surname><given-names>MC</given-names></name><name name-style="western"><surname>Kr&#228;henb&#252;hl</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal> (<year>2019</year>) <article-title>Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use</article-title>. <source>Biochem Pharmacol</source><volume>164</volume>: <fpage>129</fpage>&#8211;<lpage>138</lpage>.<pub-id pub-id-type="pmid">30981875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2019.04.013</pub-id></mixed-citation></ref><ref id="bibr69-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKenna</surname><given-names>DJ</given-names></name></person-group> (<year>2004</year>) <article-title>Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges</article-title>. <source>Pharmacol Therap</source><volume>102</volume>: <fpage>111</fpage>&#8211;<lpage>129</lpage>.<pub-id pub-id-type="pmid">15163593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2004.03.002</pub-id></mixed-citation></ref><ref id="bibr70-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKenna</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Towers</surname><given-names>GH</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>F</given-names></name></person-group> (<year>1984</year>) <article-title>Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and beta-carboline constituents of ayahuasca</article-title>. <source>J Ethnopharmacol</source><volume>10</volume>: <fpage>195</fpage>&#8211;<lpage>223</lpage>.<pub-id pub-id-type="pmid">6587171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0378-8741(84)90003-5</pub-id></mixed-citation></ref><ref id="bibr71-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moloudizargari</surname><given-names>M</given-names></name><name name-style="western"><surname>Mikaili</surname><given-names>P</given-names></name><name name-style="western"><surname>Aghajanshakeri</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal> (<year>2013</year>) <article-title>Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids</article-title>. <source>Pharmacog Rev</source><volume>7</volume>: <fpage>199</fpage>&#8211;<lpage>212</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0973-7847.120524</pub-id><pub-id pub-id-type="pmcid">PMC3841998</pub-id><pub-id pub-id-type="pmid">24347928</pub-id></mixed-citation></ref><ref id="bibr72-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphree</surname><given-names>HB</given-names></name></person-group> (<year>1962</year>) <article-title>Quantitative studies in humans on the antagonism of lysergic acid diethylamide by chlorpromazine and phenoxybenzamine</article-title>. <source>Clin Pharmacol Therap</source><volume>3</volume>: <fpage>314</fpage>&#8211;<lpage>320</lpage>.<pub-id pub-id-type="pmid">14477403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt196233314</pub-id></mixed-citation></ref><ref id="bibr73-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagai</surname><given-names>F</given-names></name><name name-style="western"><surname>Nonaka</surname><given-names>R</given-names></name><name name-style="western"><surname>Satoh Hisashi Kamimura</surname><given-names>K</given-names></name></person-group> (<year>2007</year>) <article-title>The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain</article-title>. <source>Eur J Pharmacol</source><volume>559</volume>: <fpage>132</fpage>&#8211;<lpage>137</lpage>.<pub-id pub-id-type="pmid">17223101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2006.11.075</pub-id></mixed-citation></ref><ref id="bibr74-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayak</surname><given-names>SM</given-names></name><name name-style="western"><surname>Gukasyan</surname><given-names>N</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>FS</given-names></name></person-group>, <etal>et al</etal> (<year>2021</year>) <article-title>Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: An analysis of online psychedelic experience reports</article-title>. <source>Pharmacopsychiatry</source><volume>54</volume>: <fpage>240</fpage>&#8211;<lpage>245</lpage>.<pub-id pub-id-type="pmid">34348413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1524-2794</pub-id></mixed-citation></ref><ref id="bibr75-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>J</given-names></name><name name-style="western"><surname>Straubinger</surname><given-names>RM</given-names></name><name name-style="western"><surname>Mager</surname><given-names>DE</given-names></name></person-group> (<year>2019</year>) <article-title>Pharmacodynamic drug-drug interactions</article-title>. <source>Clin Pharmacol Therap</source><volume>105</volume>: <fpage>1395</fpage>&#8211;<lpage>1406</lpage>.<pub-id pub-id-type="pmid">30912119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1434</pub-id><pub-id pub-id-type="pmcid">PMC6529235</pub-id></mixed-citation></ref><ref id="bibr76-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olbrich</surname><given-names>S</given-names></name><name name-style="western"><surname>Preller</surname><given-names>KH</given-names></name><name name-style="western"><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group> (<year>2021</year>) <article-title>LSD and ketanserin and their impact on the human autonomic nervous system</article-title>. <source>Psychophysiology</source><volume>58</volume>: e13822.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/psyp.13822</pub-id><pub-id pub-id-type="pmid">33772794</pub-id></mixed-citation></ref><ref id="bibr77-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Math&#250;na</surname><given-names>B</given-names></name><name name-style="western"><surname>Farr&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal> (<year>2008</year>) <article-title>The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans</article-title>. <source>J Clin Psychopharmacol</source><volume>28</volume>: <fpage>523</fpage>&#8211;<lpage>529</lpage>.<pub-id pub-id-type="pmid">18794647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JCP.0b013e318184ff6e</pub-id></mixed-citation></ref><ref id="bibr78-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>J</given-names></name></person-group> (<year>1996</year>) <article-title>Pharmahuasca: On phenethylamines and potentiation</article-title>. <source>Newslett MAPS</source><volume>6</volume>: <fpage>32</fpage>&#8211;<lpage>34</lpage>.</mixed-citation></ref><ref id="bibr79-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name></person-group>, <etal>et al</etal> (<year>2021</year>) <article-title>The PRISMA 2020 statement: An updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source><volume>372</volume>: n71. DOI: <pub-id pub-id-type="doi">10.1136/bmj.n71.</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id><pub-id pub-id-type="pmid">33782057</pub-id></mixed-citation></ref><ref id="bibr80-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papaliodis</surname><given-names>D</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>W</given-names></name><name name-style="western"><surname>Kempuraj</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal> (<year>2008</year>) <article-title>Niacin-induced &#8220;flush&#8221; involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model</article-title>. <source>J Pharmacol Exp</source><volume>327</volume>: <fpage>665</fpage>&#8211;<lpage>672</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.108.141333</pub-id><pub-id pub-id-type="pmid">18784348</pub-id></mixed-citation></ref><ref id="bibr81-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterfy</surname><given-names>G</given-names></name><name name-style="western"><surname>Pinter</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Pattee</surname><given-names>CJ</given-names></name></person-group> (<year>1976</year>) <article-title>Psychosomatic aspects of catecholamine depletion: Comparative studies of metabolic, endocrine and affective changes</article-title>. <source>Psychoneuroendocrinology</source><volume>1</volume>: <fpage>243</fpage>&#8211;<lpage>253</lpage>.<pub-id pub-id-type="pmid">996216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0306-4530(76)90014-7</pub-id></mixed-citation></ref><ref id="bibr82-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pokorny</surname><given-names>T</given-names></name><name name-style="western"><surname>Preller</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kraehenmann</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal> (<year>2016</year>) <article-title>Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience</article-title>. <source>Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol</source><volume>26</volume>: <fpage>756</fpage>&#8211;<lpage>766</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euroneuro.2016.01.005</pub-id><pub-id pub-id-type="pmid">26875114</pub-id></mixed-citation></ref><ref id="bibr83-02698811231211219"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Preller</surname><given-names>KH</given-names></name><name name-style="western"><surname>Burt</surname><given-names>JB</given-names></name><name name-style="western"><surname>Ji</surname><given-names>JL</given-names></name></person-group>, <etal>et al</etal> (<year>2018</year>) <article-title>Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor</article-title>. <source>ELife</source><volume>7</volume>: <publisher-name>e35082</publisher-name>. <pub-id pub-id-type="doi">10.7554/eLife.35082</pub-id><pub-id pub-id-type="pmcid">PMC6202055</pub-id><pub-id pub-id-type="pmid">30355445</pub-id></mixed-citation></ref><ref id="bibr84-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>TS</given-names></name></person-group> (<year>2010</year>) <article-title>Psychedelics and the human receptorome</article-title>. <source>PloS One</source><volume>5</volume>: e9019.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0009019</pub-id><pub-id pub-id-type="pmcid">PMC2814854</pub-id><pub-id pub-id-type="pmid">20126400</pub-id></mixed-citation></ref><ref id="bibr85-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Resnick</surname><given-names>O</given-names></name><name name-style="western"><surname>Krus</surname><given-names>DM</given-names></name><name name-style="western"><surname>Raskin</surname><given-names>M</given-names></name></person-group> (<year>1964</year>) <article-title>LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor</article-title>. <source>Life Sci</source><volume>3</volume>: <fpage>1207</fpage>&#8211;<lpage>1214</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0024-3205(64)90037-2</pub-id><pub-id pub-id-type="pmid">14231769</pub-id></mixed-citation></ref><ref id="bibr86-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Resnick</surname><given-names>O</given-names></name><name name-style="western"><surname>Krus</surname><given-names>DM</given-names></name><name name-style="western"><surname>Raskin</surname><given-names>M</given-names></name></person-group> (<year>1965</year>) <article-title>Accentuation of the psychological effects of LSD-25 in normal subjects treated with reserpine</article-title>. <source>Life Sci</source><volume>4</volume>: <fpage>1433</fpage>&#8211;<lpage>1437</lpage>.<pub-id pub-id-type="pmid">5850269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0024-3205(65)90022-6</pub-id></mixed-citation></ref><ref id="bibr87-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riba</surname><given-names>J</given-names></name><name name-style="western"><surname>McIlhenny</surname><given-names>EH</given-names></name><name name-style="western"><surname>Bouso</surname><given-names>JC</given-names></name></person-group>, <etal>et al</etal> (<year>2015</year>) <article-title>Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: A comparative study</article-title>. <source>Drug Test Anal</source><volume>7</volume>: <fpage>401</fpage>&#8211;<lpage>406</lpage>.<pub-id pub-id-type="pmid">25069786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dta.1685</pub-id></mixed-citation></ref><ref id="bibr88-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rickli</surname><given-names>A</given-names></name><name name-style="western"><surname>Moning</surname><given-names>OD</given-names></name><name name-style="western"><surname>Hoener</surname><given-names>MC</given-names></name></person-group>, <etal>et al</etal> (<year>2016</year>) <article-title>Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens</article-title>. <source>Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol</source><volume>26</volume>: <fpage>1327</fpage>&#8211;<lpage>1337</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euroneuro.2016.05.001</pub-id><pub-id pub-id-type="pmid">27216487</pub-id></mixed-citation></ref><ref id="bibr89-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivier</surname><given-names>L</given-names></name><name name-style="western"><surname>Lindgren</surname><given-names>J-E</given-names></name></person-group> (<year>1972</year>) <article-title>&#8220;Ayahuasca,&#8221; the South American hallucinogenic drink: An ethnobotanical and chemical investigation</article-title>. <source>Econ Bot</source><volume>26</volume>: <fpage>101</fpage>&#8211;<lpage>129</lpage>.</mixed-citation></ref><ref id="bibr90-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sai-Halasz</surname><given-names>A</given-names></name></person-group> (<year>1962</year>) <article-title>The effect of antiserotonin on the experimental psychosis induced by dimethyltryptamine</article-title>. <source>Experientia</source><volume>18</volume>: <fpage>137</fpage>&#8211;<lpage>138</lpage>.<pub-id pub-id-type="pmid">14496041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02153861</pub-id></mixed-citation></ref><ref id="bibr91-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sai Halasz</surname><given-names>A</given-names></name></person-group> (<year>1963</year>) <article-title>The effect of MAO inhibition on the experimental psychosis induced by dimethyltryptamine</article-title>. <source>Psychopharmacologia</source><volume>4</volume>: <fpage>385</fpage>&#8211;<lpage>388</lpage>.<pub-id pub-id-type="pmid">14048559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00405249</pub-id></mixed-citation></ref><ref id="bibr92-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakashita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Abe</surname><given-names>K</given-names></name><name name-style="western"><surname>Katagiri</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal> (<year>2015</year>) <article-title>Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats</article-title>. <source>Biol Pharm Bull</source><volume>38</volume>: <fpage>134</fpage>&#8211;<lpage>138</lpage>.<pub-id pub-id-type="pmid">25342005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1248/bpb.b14-00315</pub-id></mixed-citation></ref><ref id="bibr93-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarparast</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K</given-names></name><name name-style="western"><surname>Malcolm</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal> (<year>2022</year>) <article-title>Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review</article-title>. <source>Psychopharmacology</source><volume>239</volume>: <fpage>1945</fpage>&#8211;<lpage>1976</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-022-06083-y</pub-id><pub-id pub-id-type="pmid">35253070</pub-id><pub-id pub-id-type="pmcid">PMC9177763</pub-id></mixed-citation></ref><ref id="bibr94-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarwer-Foner</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Ogle</surname><given-names>W</given-names></name></person-group> (<year>1956</year>) <article-title>Psychosis and enhanced anxiety produced by reserpine and chlorpromazine</article-title>. <source>Can Med Assoc J</source><volume>74</volume>: <fpage>526</fpage>&#8211;<lpage>532</lpage>.<pub-id pub-id-type="pmid">13304798</pub-id><pub-id pub-id-type="pmcid">PMC1823156</pub-id></mixed-citation></ref><ref id="bibr95-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>CJ</given-names></name></person-group> (<year>1967</year>) <article-title>Paradoxical responses to chlorpromazine after LSD.pdf</article-title>. <source>Psychosomatics</source><volume>8</volume>: <fpage>210</fpage>&#8211;<lpage>211</lpage>.</mixed-citation></ref><ref id="bibr96-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sitaram</surname><given-names>BR</given-names></name><name name-style="western"><surname>Lockett</surname><given-names>L</given-names></name><name name-style="western"><surname>Talomsin</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal> (<year>1987</year>) <article-title>In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat</article-title>. <source>Biochem Pharmacol</source><volume>36</volume>: <fpage>1509</fpage>&#8211;<lpage>1512</lpage>.<pub-id pub-id-type="pmid">3472526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(87)90118-3</pub-id></mixed-citation></ref><ref id="bibr97-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sklerov</surname><given-names>J</given-names></name><name name-style="western"><surname>Levine</surname><given-names>B</given-names></name><name name-style="western"><surname>Moore</surname><given-names>KA</given-names></name></person-group>, <etal>et al</etal> (<year>2005</year>) <article-title>A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation</article-title>. <source>J Anal Toxicol</source><volume>29</volume>: <fpage>838</fpage>&#8211;<lpage>841</lpage>.<pub-id pub-id-type="pmid">16356341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jat/29.8.838</pub-id></mixed-citation></ref><ref id="bibr98-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spyraki</surname><given-names>C</given-names></name><name name-style="western"><surname>Fibiger</surname><given-names>HC</given-names></name></person-group> (<year>1981</year>) <article-title>Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine</article-title>. <source>Eur J Pharmacol</source><volume>74</volume>: <fpage>195</fpage>&#8211;<lpage>206</lpage>.<pub-id pub-id-type="pmid">7198991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0014-2999(81)90531-8</pub-id></mixed-citation></ref><ref id="bibr99-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strassman</surname><given-names>RJ</given-names></name></person-group> (<year>1984</year>) <article-title>Adverse reactions to psychedelic drugs. A review of the literature</article-title>. <source>J Nerv Ment Dis</source><volume>172</volume>: <fpage>577</fpage>&#8211;<lpage>595</lpage>.<pub-id pub-id-type="pmid">6384428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005053-198410000-00001</pub-id></mixed-citation></ref><ref id="bibr100-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strassman</surname><given-names>RJ</given-names></name></person-group> (<year>1992</year>) <article-title>Human hallucinogen interactions with drugs affecting serotonergic neurotransmission</article-title>. <source>Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol</source><volume>7</volume>: <fpage>241</fpage>&#8211;<lpage>243</lpage>.<pub-id pub-id-type="pmid">1388647</pub-id></mixed-citation></ref><ref id="bibr101-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strassman</surname><given-names>RJ</given-names></name></person-group> (<year>1996</year>) <article-title>Human psychopharmacology of N,N-dimethyltryptamine</article-title>. <source>Behav Brain Res</source><volume>73</volume>: <fpage>121</fpage>&#8211;<lpage>124</lpage>.<pub-id pub-id-type="pmid">8788488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0166-4328(96)00081-2</pub-id></mixed-citation></ref><ref id="bibr102-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Straumann</surname><given-names>I</given-names></name><name name-style="western"><surname>Ley</surname><given-names>L</given-names></name><name name-style="western"><surname>Holze</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal> (<year>2023</year>) <article-title>Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants</article-title>. <source>Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol</source><volume>48</volume>: <fpage>1840</fpage>&#8211;<lpage>1840</lpage>. <pub-id pub-id-type="doi">10.1038/s41386-023-01609-0</pub-id><pub-id pub-id-type="pmcid">PMC10584820</pub-id><pub-id pub-id-type="pmid">37258715</pub-id></mixed-citation></ref><ref id="bibr103-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vizeli</surname><given-names>P</given-names></name><name name-style="western"><surname>Straumann</surname><given-names>I</given-names></name><name name-style="western"><surname>Holze</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal> (<year>2021</year>) <article-title>Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis</article-title>. <source>Sci Rep</source><volume>11</volume>: <fpage>10851</fpage>.<pub-id pub-id-type="pmid">34035391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-90343-y</pub-id><pub-id pub-id-type="pmcid">PMC8149637</pub-id></mixed-citation></ref><ref id="bibr104-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vollenweider</surname><given-names>FX</given-names></name><name name-style="western"><surname>Smallridge</surname><given-names>JW</given-names></name></person-group> (<year>2022</year>) <article-title>Classic psychedelic drugs: Update on biological mechanisms</article-title>. <source>Pharmacopsychiatry</source><volume>55</volume>: <fpage>121</fpage>&#8211;<lpage>138</lpage>.<pub-id pub-id-type="pmid">35079988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1721-2914</pub-id><pub-id pub-id-type="pmcid">PMC9110100</pub-id></mixed-citation></ref><ref id="bibr105-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vollenweider</surname><given-names>FX</given-names></name><name name-style="western"><surname>Vollenweider-Scherpenhuyzen</surname><given-names>MF</given-names></name><name name-style="western"><surname>B&#228;bler</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal> (<year>1998</year>) <article-title>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action</article-title>. <source>Neuroreport</source><volume>9</volume>: <fpage>3897</fpage>&#8211;<lpage>3902</lpage>.<pub-id pub-id-type="pmid">9875725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00001756-199812010-00024</pub-id></mixed-citation></ref><ref id="bibr106-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagmann</surname><given-names>L</given-names></name><name name-style="western"><surname>Richter</surname><given-names>LHJ</given-names></name><name name-style="western"><surname>Kehl</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal> (<year>2019</year>) <article-title>In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures</article-title>. <source>Anal Bioanal Chem</source><volume>411</volume>: <fpage>4751</fpage>&#8211;<lpage>4763</lpage>.<pub-id pub-id-type="pmid">30617391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00216-018-1558-9</pub-id></mixed-citation></ref><ref id="bibr107-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wojtas</surname><given-names>A</given-names></name><name name-style="western"><surname>Bysiek</surname><given-names>A</given-names></name><name name-style="western"><surname>Wawrzczak-Bargiela</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal> (<year>2022</year>) <article-title>Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior</article-title>. <source>Int J Mol Sci</source><volume>23</volume>: <fpage>6713</fpage>. DOI: <pub-id pub-id-type="doi">10.3390/ijms23126713.</pub-id><pub-id pub-id-type="pmid">35743159</pub-id><pub-id pub-id-type="pmcid">PMC9224489</pub-id></mixed-citation></ref><ref id="bibr108-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyatt</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>EH</given-names></name><name name-style="western"><surname>Stoff</surname><given-names>DM</given-names></name></person-group>, <etal>et al</etal> (<year>1976</year>) <article-title>Interactions of hallucinogens at the clinical level</article-title>. <source>Ann NY Acad Sci</source><volume>281</volume>: <fpage>456</fpage>&#8211;<lpage>486</lpage>.<pub-id pub-id-type="pmid">828469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1749-6632.1976.tb27952.x</pub-id></mixed-citation></ref><ref id="bibr109-02698811231211219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal> (<year>2021</year>) <article-title>Cytochrome P450 enzymes and drug metabolism in humans</article-title>. <source>Int J Mol Sci</source><volume>22</volume>: <fpage>12808</fpage>. DOI: /10.3390/ijms222312808.<pub-id pub-id-type="pmid">34884615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms222312808</pub-id><pub-id pub-id-type="pmcid">PMC8657965</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>